US20050130207A1 - Small organometallic probes - Google Patents
Small organometallic probes Download PDFInfo
- Publication number
- US20050130207A1 US20050130207A1 US10/988,781 US98878104A US2005130207A1 US 20050130207 A1 US20050130207 A1 US 20050130207A1 US 98878104 A US98878104 A US 98878104A US 2005130207 A1 US2005130207 A1 US 2005130207A1
- Authority
- US
- United States
- Prior art keywords
- colloid
- metal
- particles
- molecules
- core particles
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000000523 sample Substances 0.000 title claims abstract description 61
- 125000002524 organometallic group Chemical group 0.000 title claims abstract description 22
- 239000010931 gold Substances 0.000 claims abstract description 72
- 229910052737 gold Inorganic materials 0.000 claims abstract description 66
- 229910052751 metal Inorganic materials 0.000 claims abstract description 66
- 239000002184 metal Substances 0.000 claims abstract description 66
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims abstract description 64
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims abstract description 31
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims abstract description 20
- 229910052709 silver Inorganic materials 0.000 claims abstract description 18
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 claims abstract description 16
- 229910052697 platinum Inorganic materials 0.000 claims abstract description 16
- 239000004332 silver Substances 0.000 claims abstract description 16
- 229910052763 palladium Inorganic materials 0.000 claims abstract description 10
- 239000000084 colloidal system Substances 0.000 claims description 57
- 238000000034 method Methods 0.000 claims description 55
- 150000003573 thiols Chemical class 0.000 claims description 43
- 239000007771 core particle Substances 0.000 claims description 40
- 239000000203 mixture Substances 0.000 claims description 40
- 239000000126 substance Substances 0.000 claims description 34
- 239000002245 particle Substances 0.000 claims description 33
- 108020004707 nucleic acids Proteins 0.000 claims description 29
- 150000007523 nucleic acids Chemical class 0.000 claims description 29
- 102000039446 nucleic acids Human genes 0.000 claims description 29
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims description 22
- 229920000642 polymer Polymers 0.000 claims description 21
- 238000001493 electron microscopy Methods 0.000 claims description 20
- 230000008569 process Effects 0.000 claims description 20
- 235000018102 proteins Nutrition 0.000 claims description 20
- 102000004169 proteins and genes Human genes 0.000 claims description 20
- 108090000623 proteins and genes Proteins 0.000 claims description 20
- -1 polyethylene Chemical class 0.000 claims description 16
- 239000002923 metal particle Substances 0.000 claims description 15
- 125000000524 functional group Chemical group 0.000 claims description 13
- 150000002632 lipids Chemical class 0.000 claims description 13
- 238000006243 chemical reaction Methods 0.000 claims description 12
- 238000003786 synthesis reaction Methods 0.000 claims description 12
- 108010024636 Glutathione Proteins 0.000 claims description 11
- 108010090804 Streptavidin Proteins 0.000 claims description 11
- 239000011248 coating agent Substances 0.000 claims description 11
- 238000000576 coating method Methods 0.000 claims description 11
- 229960003180 glutathione Drugs 0.000 claims description 11
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 10
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 10
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 10
- 210000004027 cell Anatomy 0.000 claims description 9
- 238000000386 microscopy Methods 0.000 claims description 9
- 210000001519 tissue Anatomy 0.000 claims description 9
- ABXYOVCSAGTJAC-JGWLITMVSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanethial Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=S ABXYOVCSAGTJAC-JGWLITMVSA-N 0.000 claims description 8
- 238000004624 confocal microscopy Methods 0.000 claims description 8
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 8
- 238000009826 distribution Methods 0.000 claims description 7
- 230000004807 localization Effects 0.000 claims description 7
- 210000000056 organ Anatomy 0.000 claims description 7
- 210000003463 organelle Anatomy 0.000 claims description 7
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 6
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 claims description 6
- 229940079593 drug Drugs 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 238000010438 heat treatment Methods 0.000 claims description 6
- 239000007787 solid Substances 0.000 claims description 6
- 150000001720 carbohydrates Chemical class 0.000 claims description 5
- 235000014633 carbohydrates Nutrition 0.000 claims description 5
- 229940088597 hormone Drugs 0.000 claims description 5
- 239000005556 hormone Substances 0.000 claims description 5
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 claims description 4
- 239000004698 Polyethylene Chemical class 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 4
- 239000000427 antigen Substances 0.000 claims description 4
- 102000036639 antigens Human genes 0.000 claims description 4
- 108091007433 antigens Proteins 0.000 claims description 4
- 238000000799 fluorescence microscopy Methods 0.000 claims description 4
- 229920000573 polyethylene Chemical class 0.000 claims description 4
- 238000012360 testing method Methods 0.000 claims description 4
- GVJXGCIPWAVXJP-UHFFFAOYSA-N 2,5-dioxo-1-oxoniopyrrolidine-3-sulfonate Chemical compound ON1C(=O)CC(S(O)(=O)=O)C1=O GVJXGCIPWAVXJP-UHFFFAOYSA-N 0.000 claims description 3
- GDSOQCSYONDNAJ-UHFFFAOYSA-N 2-thiophen-2-ylbenzoic acid Chemical compound OC(=O)C1=CC=CC=C1C1=CC=CS1 GDSOQCSYONDNAJ-UHFFFAOYSA-N 0.000 claims description 3
- 108090001008 Avidin Proteins 0.000 claims description 3
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 3
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 3
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 claims description 3
- 150000001356 alkyl thiols Chemical class 0.000 claims description 3
- 150000001504 aryl thiols Chemical class 0.000 claims description 3
- 239000013522 chelant Substances 0.000 claims description 3
- 238000010382 chemical cross-linking Methods 0.000 claims description 3
- 238000007385 chemical modification Methods 0.000 claims description 3
- 229910017052 cobalt Inorganic materials 0.000 claims description 3
- 239000010941 cobalt Substances 0.000 claims description 3
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 claims description 3
- 229910052802 copper Inorganic materials 0.000 claims description 3
- 239000010949 copper Substances 0.000 claims description 3
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 3
- 235000018417 cysteine Nutrition 0.000 claims description 3
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 claims description 3
- 239000007850 fluorescent dye Substances 0.000 claims description 3
- 229910052742 iron Inorganic materials 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 230000004048 modification Effects 0.000 claims description 3
- 229910052759 nickel Inorganic materials 0.000 claims description 3
- 229920001308 poly(aminoacid) Chemical class 0.000 claims description 3
- 238000006116 polymerization reaction Methods 0.000 claims description 3
- 229910052723 transition metal Inorganic materials 0.000 claims description 3
- 150000003624 transition metals Chemical class 0.000 claims description 3
- 238000010792 warming Methods 0.000 claims description 3
- 239000013078 crystal Substances 0.000 claims description 2
- 230000002255 enzymatic effect Effects 0.000 claims description 2
- 239000000758 substrate Substances 0.000 claims description 2
- 230000002194 synthesizing effect Effects 0.000 claims description 2
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 claims 2
- 238000001668 nucleic acid synthesis Methods 0.000 claims 2
- 230000000087 stabilizing effect Effects 0.000 claims 2
- 238000003556 assay Methods 0.000 claims 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 abstract description 12
- 230000008685 targeting Effects 0.000 abstract description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 102
- 239000000243 solution Substances 0.000 description 90
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 75
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 49
- 229910001868 water Inorganic materials 0.000 description 34
- 239000012279 sodium borohydride Substances 0.000 description 29
- 229910000033 sodium borohydride Inorganic materials 0.000 description 29
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 28
- 238000002360 preparation method Methods 0.000 description 27
- 239000011541 reaction mixture Substances 0.000 description 27
- 239000000872 buffer Substances 0.000 description 26
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 24
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 24
- 238000002523 gelfiltration Methods 0.000 description 22
- 239000012528 membrane Substances 0.000 description 21
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 20
- 239000000047 product Substances 0.000 description 20
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 18
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 18
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 18
- AFQIYTIJXGTIEY-UHFFFAOYSA-N hydrogen carbonate;triethylazanium Chemical compound OC(O)=O.CCN(CC)CC AFQIYTIJXGTIEY-UHFFFAOYSA-N 0.000 description 18
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 16
- 239000001488 sodium phosphate Substances 0.000 description 16
- 229910000162 sodium phosphate Inorganic materials 0.000 description 16
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 16
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 15
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 15
- 239000000499 gel Substances 0.000 description 15
- 230000015572 biosynthetic process Effects 0.000 description 14
- 150000001875 compounds Chemical class 0.000 description 14
- 239000011780 sodium chloride Substances 0.000 description 14
- 241000894007 species Species 0.000 description 14
- 239000003446 ligand Substances 0.000 description 13
- SLKDGVPOSSLUAI-PGUFJCEWSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphoethanolamine zwitterion Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OCCN)OC(=O)CCCCCCCCCCCCCCC SLKDGVPOSSLUAI-PGUFJCEWSA-N 0.000 description 11
- 239000012634 fragment Substances 0.000 description 11
- 238000001542 size-exclusion chromatography Methods 0.000 description 11
- 239000011800 void material Substances 0.000 description 11
- 229960001701 chloroform Drugs 0.000 description 10
- 229910000073 phosphorus hydride Inorganic materials 0.000 description 10
- 108091034117 Oligonucleotide Proteins 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 239000007983 Tris buffer Substances 0.000 description 9
- 238000002372 labelling Methods 0.000 description 9
- 125000000962 organic group Chemical group 0.000 description 9
- 229960002685 biotin Drugs 0.000 description 8
- 235000020958 biotin Nutrition 0.000 description 8
- 239000011616 biotin Substances 0.000 description 8
- 239000008367 deionised water Substances 0.000 description 8
- 229910021641 deionized water Inorganic materials 0.000 description 8
- 150000003141 primary amines Chemical class 0.000 description 8
- 239000012064 sodium phosphate buffer Substances 0.000 description 8
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 7
- 229940098773 bovine serum albumin Drugs 0.000 description 7
- 230000021615 conjugation Effects 0.000 description 7
- 238000001514 detection method Methods 0.000 description 7
- 238000011161 development Methods 0.000 description 7
- 230000018109 developmental process Effects 0.000 description 7
- ZMANZCXQSJIPKH-UHFFFAOYSA-O triethylammonium ion Chemical compound CC[NH+](CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-O 0.000 description 7
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 7
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 6
- 229960000583 acetic acid Drugs 0.000 description 6
- 238000011534 incubation Methods 0.000 description 6
- 125000003729 nucleotide group Chemical group 0.000 description 6
- JUSMHIGDXPKSID-DVKNGEFBSA-N 1-thio-beta-D-glucopyranose Chemical compound OC[C@H]1O[C@@H](S)[C@H](O)[C@@H](O)[C@@H]1O JUSMHIGDXPKSID-DVKNGEFBSA-N 0.000 description 5
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 5
- 239000007995 HEPES buffer Substances 0.000 description 5
- 239000012062 aqueous buffer Substances 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 5
- 239000012153 distilled water Substances 0.000 description 5
- 239000012149 elution buffer Substances 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000002953 phosphate buffered saline Substances 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 241000283707 Capra Species 0.000 description 4
- 239000000020 Nitrocellulose Substances 0.000 description 4
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 4
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 4
- 125000003118 aryl group Chemical group 0.000 description 4
- 150000002343 gold Chemical class 0.000 description 4
- 238000010348 incorporation Methods 0.000 description 4
- 150000002739 metals Chemical class 0.000 description 4
- 230000007935 neutral effect Effects 0.000 description 4
- 229920001220 nitrocellulos Polymers 0.000 description 4
- CLSUSRZJUQMOHH-UHFFFAOYSA-L platinum dichloride Chemical compound Cl[Pt]Cl CLSUSRZJUQMOHH-UHFFFAOYSA-L 0.000 description 4
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 4
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical class C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 4
- PFKFTWBEEFSNDU-UHFFFAOYSA-N 1,1'-Carbonyldiimidazole Substances C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 3
- OGMADIBCHLQMIP-UHFFFAOYSA-N 2-aminoethanethiol;hydron;chloride Chemical compound Cl.NCCS OGMADIBCHLQMIP-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- GHAZCVNUKKZTLG-UHFFFAOYSA-N N-ethyl-succinimide Natural products CCN1C(=O)CCC1=O GHAZCVNUKKZTLG-UHFFFAOYSA-N 0.000 description 3
- HDFGOPSGAURCEO-UHFFFAOYSA-N N-ethylmaleimide Chemical compound CCN1C(=O)C=CC1=O HDFGOPSGAURCEO-UHFFFAOYSA-N 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 230000002776 aggregation Effects 0.000 description 3
- 238000004220 aggregation Methods 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 239000003638 chemical reducing agent Substances 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 230000008020 evaporation Effects 0.000 description 3
- 230000007717 exclusion Effects 0.000 description 3
- 238000005194 fractionation Methods 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 239000012362 glacial acetic acid Substances 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- LLAZQXZGAVBLRX-UHFFFAOYSA-N methyl 2,5-dioxopyrrole-1-carboxylate Chemical compound COC(=O)N1C(=O)C=CC1=O LLAZQXZGAVBLRX-UHFFFAOYSA-N 0.000 description 3
- NCGWKCHAJOUDHQ-UHFFFAOYSA-N n,n-diethylethanamine;formic acid Chemical compound OC=O.OC=O.CCN(CC)CC NCGWKCHAJOUDHQ-UHFFFAOYSA-N 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 150000003003 phosphines Chemical class 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000035939 shock Effects 0.000 description 3
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 3
- ZNJHFNUEQDVFCJ-UHFFFAOYSA-M sodium;2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid;hydroxide Chemical compound [OH-].[Na+].OCCN1CCN(CCS(O)(=O)=O)CC1 ZNJHFNUEQDVFCJ-UHFFFAOYSA-M 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- NBOMNTLFRHMDEZ-UHFFFAOYSA-N thiosalicylic acid Chemical compound OC(=O)C1=CC=CC=C1S NBOMNTLFRHMDEZ-UHFFFAOYSA-N 0.000 description 3
- 150000005045 1,10-phenanthrolines Chemical group 0.000 description 2
- CIEMDIKTFOLQML-UHFFFAOYSA-N 2-amino-1-sulfanylethanol Chemical compound NCC(O)S CIEMDIKTFOLQML-UHFFFAOYSA-N 0.000 description 2
- AUUIARVPJHGTSA-UHFFFAOYSA-N 3-(aminomethyl)chromen-2-one Chemical compound C1=CC=C2OC(=O)C(CN)=CC2=C1 AUUIARVPJHGTSA-UHFFFAOYSA-N 0.000 description 2
- DHDHJYNTEFLIHY-UHFFFAOYSA-N 4,7-diphenyl-1,10-phenanthroline Chemical compound C1=CC=CC=C1C1=CC=NC2=C1C=CC1=C(C=3C=CC=CC=3)C=CN=C21 DHDHJYNTEFLIHY-UHFFFAOYSA-N 0.000 description 2
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 2
- 239000005695 Ammonium acetate Substances 0.000 description 2
- XHVAWZZCDCWGBK-WYRLRVFGSA-M Aurothioglucose Chemical compound OC[C@H]1O[C@H](S[Au])[C@H](O)[C@@H](O)[C@@H]1O XHVAWZZCDCWGBK-WYRLRVFGSA-M 0.000 description 2
- AHCYMLUZIRLXAA-SHYZEUOFSA-N Deoxyuridine 5'-triphosphate Chemical class O1[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(=O)NC(=O)C=C1 AHCYMLUZIRLXAA-SHYZEUOFSA-N 0.000 description 2
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 2
- 229910004042 HAuCl4 Inorganic materials 0.000 description 2
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 229940043376 ammonium acetate Drugs 0.000 description 2
- 235000019257 ammonium acetate Nutrition 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 229960001799 aurothioglucose Drugs 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 230000001588 bifunctional effect Effects 0.000 description 2
- VYLDEYYOISNGST-UHFFFAOYSA-N bissulfosuccinimidyl suberate Chemical compound O=C1C(S(=O)(=O)O)CC(=O)N1OC(=O)CCCCCCC(=O)ON1C(=O)C(S(O)(=O)=O)CC1=O VYLDEYYOISNGST-UHFFFAOYSA-N 0.000 description 2
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- SBZXBUIDTXKZTM-UHFFFAOYSA-N diglyme Chemical compound COCCOCCOC SBZXBUIDTXKZTM-UHFFFAOYSA-N 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- PQTCMBYFWMFIGM-UHFFFAOYSA-N gold silver Chemical compound [Ag].[Au] PQTCMBYFWMFIGM-UHFFFAOYSA-N 0.000 description 2
- 239000011544 gradient gel Substances 0.000 description 2
- ARBOVOVUTSQWSS-UHFFFAOYSA-N hexadecanoyl chloride Chemical compound CCCCCCCCCCCCCCCC(Cl)=O ARBOVOVUTSQWSS-UHFFFAOYSA-N 0.000 description 2
- 238000003119 immunoblot Methods 0.000 description 2
- 238000004255 ion exchange chromatography Methods 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- ZVEZMVFBMOOHAT-UHFFFAOYSA-N nonane-1-thiol Chemical compound CCCCCCCCCS ZVEZMVFBMOOHAT-UHFFFAOYSA-N 0.000 description 2
- 150000005041 phenanthrolines Chemical class 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 239000002516 radical scavenger Substances 0.000 description 2
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 239000010944 silver (metal) Substances 0.000 description 2
- CQLFBEKRDQMJLZ-UHFFFAOYSA-M silver acetate Chemical compound [Ag+].CC([O-])=O CQLFBEKRDQMJLZ-UHFFFAOYSA-M 0.000 description 2
- 229940071536 silver acetate Drugs 0.000 description 2
- OGFYIDCVDSATDC-UHFFFAOYSA-N silver silver Chemical compound [Ag].[Ag] OGFYIDCVDSATDC-UHFFFAOYSA-N 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 239000001226 triphosphate Substances 0.000 description 2
- 235000011178 triphosphate Nutrition 0.000 description 2
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- YMXHPSHLTSZXKH-RVBZMBCESA-N (2,5-dioxopyrrolidin-1-yl) 5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoate Chemical compound C([C@H]1[C@H]2NC(=O)N[C@H]2CS1)CCCC(=O)ON1C(=O)CCC1=O YMXHPSHLTSZXKH-RVBZMBCESA-N 0.000 description 1
- UVGHPGOONBRLCX-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 6-[5-(2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl)pentanoylamino]hexanoate Chemical compound S1CC2NC(=O)NC2C1CCCCC(=O)NCCCCCC(=O)ON1C(=O)CCC1=O UVGHPGOONBRLCX-UHFFFAOYSA-N 0.000 description 1
- NGEZPLCPKXKLQQ-VOTSOKGWSA-N (e)-4-(3-methoxyphenyl)but-3-en-2-one Chemical compound COC1=CC=CC(\C=C\C(C)=O)=C1 NGEZPLCPKXKLQQ-VOTSOKGWSA-N 0.000 description 1
- KLFRPGNCEJNEKU-FDGPNNRMSA-L (z)-4-oxopent-2-en-2-olate;platinum(2+) Chemical compound [Pt+2].C\C([O-])=C\C(C)=O.C\C([O-])=C\C(C)=O KLFRPGNCEJNEKU-FDGPNNRMSA-L 0.000 description 1
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 1
- 150000003923 2,5-pyrrolediones Chemical group 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- PHFLXIQFEQHVNZ-UHFFFAOYSA-K CNC(=O)C1=C2C=CC3=C(C(=O)NCCCN)C=CN=C3C2=NC=C1.CNC(=O)C1=C2C=CC3=C(C(C)=O)C=CN=C3C2=NC=C1.O=S(=O)([O-])C1=CC=C(C2=C3C=CC4=C(C5=CC=C([Na-2](OO)OS)C=C5)C=CN=C4C3=NC=C2)C=C1.[Na+] Chemical compound CNC(=O)C1=C2C=CC3=C(C(=O)NCCCN)C=CN=C3C2=NC=C1.CNC(=O)C1=C2C=CC3=C(C(C)=O)C=CN=C3C2=NC=C1.O=S(=O)([O-])C1=CC=C(C2=C3C=CC4=C(C5=CC=C([Na-2](OO)OS)C=C5)C=CN=C4C3=NC=C2)C=C1.[Na+] PHFLXIQFEQHVNZ-UHFFFAOYSA-K 0.000 description 1
- 239000004971 Cross linker Substances 0.000 description 1
- XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 description 1
- 239000003298 DNA probe Substances 0.000 description 1
- 239000001263 FEMA 3042 Substances 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000007999 Nuclear Proteins Human genes 0.000 description 1
- 108010089610 Nuclear Proteins Proteins 0.000 description 1
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 1
- 241001135910 Phage M13mp18 Species 0.000 description 1
- 229920002873 Polyethylenimine Polymers 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000012505 Superdex™ Substances 0.000 description 1
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000004847 absorption spectroscopy Methods 0.000 description 1
- 238000000862 absorption spectrum Methods 0.000 description 1
- CUJRVFIICFDLGR-UHFFFAOYSA-N acetylacetonate Chemical compound CC(=O)[CH-]C(C)=O CUJRVFIICFDLGR-UHFFFAOYSA-N 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 230000001745 anti-biotin effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 229910021538 borax Inorganic materials 0.000 description 1
- 230000005587 bubbling Effects 0.000 description 1
- 239000000337 buffer salt Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 239000002026 chloroform extract Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 230000001268 conjugating effect Effects 0.000 description 1
- IPIVAXLHTVNRBS-UHFFFAOYSA-N decanoyl chloride Chemical compound CCCCCCCCCC(Cl)=O IPIVAXLHTVNRBS-UHFFFAOYSA-N 0.000 description 1
- HTWWKYKIBSHDPC-UHFFFAOYSA-N decanoyl decanoate Chemical compound CCCCCCCCCC(=O)OC(=O)CCCCCCCCC HTWWKYKIBSHDPC-UHFFFAOYSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- NWADXBLMWHFGGU-UHFFFAOYSA-N dodecanoic anhydride Chemical compound CCCCCCCCCCCC(=O)OC(=O)CCCCCCCCCCC NWADXBLMWHFGGU-UHFFFAOYSA-N 0.000 description 1
- NQGIJDNPUZEBRU-UHFFFAOYSA-N dodecanoyl chloride Chemical compound CCCCCCCCCCCC(Cl)=O NQGIJDNPUZEBRU-UHFFFAOYSA-N 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- NLFBCYMMUAKCPC-KQQUZDAGSA-N ethyl (e)-3-[3-amino-2-cyano-1-[(e)-3-ethoxy-3-oxoprop-1-enyl]sulfanyl-3-oxoprop-1-enyl]sulfanylprop-2-enoate Chemical compound CCOC(=O)\C=C\SC(=C(C#N)C(N)=O)S\C=C\C(=O)OCC NLFBCYMMUAKCPC-KQQUZDAGSA-N 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000005189 flocculation Methods 0.000 description 1
- 230000016615 flocculation Effects 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 235000003969 glutathione Nutrition 0.000 description 1
- 229940111120 gold preparations Drugs 0.000 description 1
- IZLAVFWQHMDDGK-UHFFFAOYSA-N gold(1+);cyanide Chemical compound [Au+].N#[C-] IZLAVFWQHMDDGK-UHFFFAOYSA-N 0.000 description 1
- IFPWCRBNZXUWGC-UHFFFAOYSA-M gold(1+);triphenylphosphane;chloride Chemical compound [Cl-].[Au+].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 IFPWCRBNZXUWGC-UHFFFAOYSA-M 0.000 description 1
- ICDQUAGMQCUEMY-UHFFFAOYSA-N heptadecanoyl chloride Chemical compound CCCCCCCCCCCCCCCCC(Cl)=O ICDQUAGMQCUEMY-UHFFFAOYSA-N 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 229940127121 immunoconjugate Drugs 0.000 description 1
- PGLTVOMIXTUURA-UHFFFAOYSA-N iodoacetamide Chemical compound NC(=O)CI PGLTVOMIXTUURA-UHFFFAOYSA-N 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 150000002500 ions Chemical group 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 125000005439 maleimidyl group Chemical group C1(C=CC(N1*)=O)=O 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- ZIUHHBKFKCYYJD-UHFFFAOYSA-N n,n'-methylenebisacrylamide Chemical compound C=CC(=O)NCNC(=O)C=C ZIUHHBKFKCYYJD-UHFFFAOYSA-N 0.000 description 1
- NTQYXUJLILNTFH-UHFFFAOYSA-N nonanoyl chloride Chemical compound CCCCCCCCC(Cl)=O NTQYXUJLILNTFH-UHFFFAOYSA-N 0.000 description 1
- WTBAHSZERDXKKZ-UHFFFAOYSA-N octadecanoyl chloride Chemical compound CCCCCCCCCCCCCCCCCC(Cl)=O WTBAHSZERDXKKZ-UHFFFAOYSA-N 0.000 description 1
- WVJVHUWVQNLPCR-UHFFFAOYSA-N octadecanoyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC(=O)CCCCCCCCCCCCCCCCC WVJVHUWVQNLPCR-UHFFFAOYSA-N 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- LXNAVEXFUKBNMK-UHFFFAOYSA-N palladium(II) acetate Substances [Pd].CC(O)=O.CC(O)=O LXNAVEXFUKBNMK-UHFFFAOYSA-N 0.000 description 1
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 150000008300 phosphoramidites Chemical class 0.000 description 1
- 150000003058 platinum compounds Chemical class 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 235000010339 sodium tetraborate Nutrition 0.000 description 1
- VRVKOZSIJXBAJG-ODZAUARKSA-M sodium;(z)-but-2-enedioate;hydron Chemical compound [Na+].OC(=O)\C=C/C([O-])=O VRVKOZSIJXBAJG-ODZAUARKSA-M 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- TYFQFVWCELRYAO-UHFFFAOYSA-L suberate(2-) Chemical compound [O-]C(=O)CCCCCCC([O-])=O TYFQFVWCELRYAO-UHFFFAOYSA-L 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 description 1
- 229920002258 tannic acid Polymers 0.000 description 1
- 229940033123 tannic acid Drugs 0.000 description 1
- 235000015523 tannic acid Nutrition 0.000 description 1
- 229910052716 thallium Inorganic materials 0.000 description 1
- BKVIYDNLLOSFOA-UHFFFAOYSA-N thallium Chemical compound [Tl] BKVIYDNLLOSFOA-UHFFFAOYSA-N 0.000 description 1
- GBECUEIQVRDUKB-UHFFFAOYSA-M thallium monochloride Chemical compound [Tl]Cl GBECUEIQVRDUKB-UHFFFAOYSA-M 0.000 description 1
- NJRXVEJTAYWCQJ-UHFFFAOYSA-N thiomalic acid Chemical compound OC(=O)CC(S)C(O)=O NJRXVEJTAYWCQJ-UHFFFAOYSA-N 0.000 description 1
- ILWRPSCZWQJDMK-UHFFFAOYSA-N triethylazanium;chloride Chemical compound Cl.CCN(CC)CC ILWRPSCZWQJDMK-UHFFFAOYSA-N 0.000 description 1
- BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 1
- 229910052721 tungsten Inorganic materials 0.000 description 1
- 238000002371 ultraviolet--visible spectrum Methods 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
- A61B6/48—Diagnostic techniques
- A61B6/481—Diagnostic techniques involving the use of contrast agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
- A61K47/544—Phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/04—X-ray contrast preparations
- A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
- A61K49/0447—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is a halogenated organic compound
- A61K49/0476—Particles, beads, capsules, spheres
- A61K49/0485—Nanoparticles, nanobeads, nanospheres, nanocapsules, i.e. having a size or diameter smaller than 1 micrometer
- A61K49/049—Surface-modified nanoparticles, e.g. immune-nanoparticles
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y30/00—Nanotechnology for materials or surface science, e.g. nanocomposites
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F1/00—Compounds containing elements of Groups 1 or 11 of the Periodic Table
- C07F1/005—Compounds containing elements of Groups 1 or 11 of the Periodic Table without C-Metal linkages
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/50—Organo-phosphines
- C07F9/5022—Aromatic phosphines (P-C aromatic linkage)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6816—Hybridisation assays characterised by the detection means
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
- G01N33/532—Production of labelled immunochemicals
- G01N33/533—Production of labelled immunochemicals with fluorescent label
Definitions
- colloids do not have a fixed number of metal atoms and vary considerably in size.
- the metal colloids could vary in size from 1 nm to 2 ⁇ m in size and could contain from about 10 metal atoms to thousands of metal atoms, depending on size. It was found that a number of proteins, such as IgG antibodies, could be adsorbed to these sol particles.
- Gold colloids have been most commonly described. These conjugates have been used in electron and light microscopy as well as on immunodot blots for detection of target molecules. These conjugates have many shortcomings. Since the molecules are only adsorbed onto the colloids, they also desorb to varying extents.
- the ‘sticky’ colloids also tend to aggregate. If fluorescence is used to detect the target molecules, the gold particles quench most of it. Also, the gold colloids must be stabilized against dramatic aggregation or ‘flocculation’ when salts are added by adsorbing bulky proteins, such as bovine serum albumin. Due to the effects of aggregation and bulky additives, the penetration of immunoprobes into tissues is generally ⁇ 0.5 ⁇ m. Accessibility of the probes to internal cell structures, e.g., nuclear proteins, or to cells deeper in a tissue sample, is impeded by these properties.
- Colloidal gold immunoprobes are also used in diagnosis on blots.
- the sensitivity of these detection schemes is again degraded by problems of aggregation, detachment of antibodies from the gold, and problems with shelf life.
- the gold prepared in standard ways also has low activity due to few adsorbed antibodies and denaturation of some antibodies during adsorption.
- NanogoldTM Another metal cluster compound which has been used as a probe is NanogoldTM available from the assignee of the present application.
- NanogoldTM has a metal core with 50-70 gold atoms (the exact number not yet being known but believed to be 67 gold atoms) surrounded by a similar shell of organic groups (PAr 3 ) as undecagold.
- the metal core of NanogoldTM is 1.4 nm in diameter.
- the production of Nanogold is described in U.S. Pat. No. 5,360,895, of James F. Hainfeld and Frederic R. Furuya.
- the invention in a preferred form is a cluster complex or colloid including metal core particles and probe molecules covalently attached to the core particles.
- the probe molecules functionalize the cluster complex or colloid to target at least one other substance or to endow the particles with specified properties.
- the core particles are less than 2 microns in size and may be composed of gold, platinum, silver, palladium, or combinations thereof.
- the probe molecules may be covalently bonded to the core particles by a specific reaction of the probe molecules with a functional group incorporated into an outer surface of the core particle by means of chemical synthesis or modification.
- the functional group may be maleimide, N-hydroxysuccinimide, Sulfo-N-hydroxysuccinimide, aliphatic amine, 1,2-dihydroxy, aldehyde, nitrilotriaceitic acid (NTA) or its chelate with nickel, copper, iron, cobalt, or other transition metal.
- the probe molecules may be antibodies, antibody fragments, avidin or streptavidin, peptides, drugs, antigens, hormones, DNA, and RNA.
- the clusters or colloids may also include fluorescently labeled molecules covalently attached to the core particles, where the chemistry for covalently attaching the probe molecules and the fluorescently labeled molecules to the core particles controls the fluorophore of the fluorescently labeled molecules.
- the cluster complex or colloid may also include a polymer coating the core particles, the polymer being chosen from a group containing linear or branched polymer with functional groups, polyamino acids, polyethylene derivatives, and mixtures thereof.
- the invention is also a method for detecting a substance, where a sample suspected of containing the substance is mixed with a cluster complex or a colloid having metal core particles and probe molecules covalently attached to the core particles, the probe molecules functionalizing the cluster complex or colloid to target the substance.
- the method may include detecting the substance with a piezoelectric crystal mass measuring device, detecting the substance by using changes in reflected light from a surface, detecting the substance using light microscopy, detecting the substance using fluorescent microscopy, detecting the substance using confocal microscopy, or detecting the substance using electron microscopy.
- the method may include visualizing the localization or distribution of the substance within cells, tissue sections, organelles or organs using light microscopy, using fluorescent microscopy, or using confocal microscopy, using electron microscopy.
- the method may include detecting the substance using both light, fluorescence or confocal microscopy and electron microscopy, the cluster complex or colloid also including fluorescently labeled molecules covalently attached to the core particles, where the chemistry for covalently attaching the probe molecules and the fluorescently labeled molecules to the core particles controls the fluorophore of the fluorescently labeled molecules.
- the method may include visualizing the localization or distribution of the substance within cells, tissue sections, organelles or organs using both light, fluorescence or confocal microscopy and electron microscopy, the cluster complex or colloid also including fluorescently labeled molecules covalently attached to the core particles, where the chemistry for covalently attaching the probe molecules and the fluorescently labeled molecules to the core particles controls the fluorophore of the fluorescently labeled molecules.
- “Thiol gold clusters” are novel gold clusters produced by a novel synthesis. The procedure is: form an organic-gold complex by reacting a compound containing a thiol with gold in solution. A second equivalent is also added of the thiol compound. Finally the gold organic is reduced with NaBH 4 or other reducing agents and organometallic particles are formed. These have the general formula Au n R m R′ i . . .
- R and R′ are organic thiols, (e.g., alkyl thiols, aryl thiols, proteins containing thiol, peptides or nucleic acids with thiol, glutathione, cysteine, thioglucose, thiol benzoic acid, etc.) and the ellipsis indicates that one or more organic thiols may be used.
- organic thiol compound clusters with gold cores ⁇ 1.4 nm are formed with many organics.
- the organic moiety may then be reacted by usual reactions to covalently link this particle to antibodies, lipids, carbohydrates, nucleic acids, or other molecules to form probes.
- Mixtures of organic thiols may be used to provide mixed functionality to the clusters. These organo-gold clusters are stable to heating at 100° C.
- the thiol-gold preparation described in #1 above may be altered such that a larger molar ratio of organic thiol to gold is used. Ratios above approximately 2:1 or below 1:2 result in organic-gold colloids whose size depends on this ratio. These are useful when large gold particles are desired.
- organic thiol-gold preparations described in #'s 1 and 2 above may be made using a similar process with alternatives metals to gold, e.g., platinum, silver, palladium and other metals.
- organic thiol-metal particles described in #'s 1, 2, and 3 above may be made using mixtures of metal ions, e.g., gold and silver, resulting in mixed metal clusters.
- a novel process has been developed for coating colloidal particles (of various types including gold, silver, and other metals) with organic moieties having groups suitable for covalently attaching additional molecules, such as antibodies, nucleic acids, lipids, peptides, and other proteins.
- the process consists of synthesizing the metal colloid in the presence of a suitable polymer, e.g., HAuCl 4 (0.01%) in 0.05M sodium hydrogen maleate buffer (pH 6.0), with 0.004% tannic acid.
- the polymer may be chosen from a linear or branched group with functional groups attached, such as polyamino acids, polyethylene derivatives, other polymers, or mixtures thereof.
- Optimal molecular weight of the polymer varies with the specific ones chosen.
- a second method is to synthesize the metal particle first, e.g., by combining 0.01% HAuCl 4 with 1% sodium citrate with heating.
- gold colloid is formed of the desired size, it is coated with one of the above polymers by mixing the two together and optionally warming to 60°-100° C. for several minutes.
- the polymer coating may be further stabilized by a) microwave heating, b) further chemical crosslinking, e.g., by glutaraldehyde or other linkers, or by continued polymerization adding substrate molecules for a brief period.
- Use of N, N′-methylene bis acrylamide, for example, can covalently further stabilize the polymer coating.
- Photocrosslinking may also be used.
- the functionalized polymer coating may now be used to covalently attach proteins, peptides, antibodies, lipids, carbohydrates, nucleic acids, drugs, hormones, or other substances. This has the advantage that this step may be done mildly, in physiological buffers if desired, using standard crosslinking technology. This eliminates the usual restriction that conjugation must be performed in very low ionic strength buffers, which precludes attachment of certain molecules such as many IgM's which cannot withstand the low ionic strength requirement.
- organic coupling moieties e.g., triphenyl phosphines 1,10 phenanthrolines, triphenyl phosphines or phenanthrolines containing linkable groups such as amines or carboxyls, triphenyl phosphines or 1,10 phenanthrolines containing reactive groups such as maleimides or N-hydroxysuccinimide esters, P(C 6 H 4 —CO—NH—(CH 2 ) 3 —NH 2 ) 3 , P(C 6 H 4 —CO—NH—CH 3 ) 2 (C 6 H 4 —CO—NH—(CH 2 ) 3 —NH 2 ), P(C 6 H 4 —CO—N H—(CH 2 ) 3 —NC 4 O 2 H 2 ) 3 , P(C 6 H 4 —CO—NH—(CH 2 ) 3 —NH—(CH 2 ) 6 —CO 2 —NC 4 O 2 H 4 ) 3 , etc.), Or
- Or, Or′, and Or′′ may be the same or different.
- the subscripts 1, n, m and p indicate that multiple copies of each moiety are possible and include mixtures of different metals, fluorescent groups, organic groups and targeting molecules for multifunctional conjugates.
- a specific example of this is: Au 11 [Pph(CONHCH 3 )] 6 phCONH(CH 2 ) 3 NH—F, where ph is a phenyl group, and F is a fluorescent molecule.
- a process to produce such multifunctional metal particles is as follows: a metal cluster or metal colloid is synthesized having one or more reactive groups such as an amine or carboxyl. These are then reacted to covalently link a fluorescent molecule molecule such as fluorescein, Texas Red, rhodamine, or aminomethyl coumarin, and optionally a targeting or other molecule is covalently attached such as an antibody or antibody fragment, a peptide, streptavidin, or other proteins, a nucleic acid (RNA or DNA), drugs, hormones, or other molecules.
- the fluorescent groups may be incorporated into ligands which are then used to prepare the cluster.
- Lipid molecules are covalently attached to metal particles (clusters or coated reactive colloids).
- This process uses a reactive lipid derivative, e.g., a sulfonyl chloride or anhydride, which is reacted with an amino group, for example, on the metal particle.
- organic groups on the metal particle or lipid may be reacted with bifunctional crosslinkers which are then reacted with the other species.
- Another process is to presynthesize the organic components of the metal particles (e.g., phosphines or polymers) with lipid molecules attached and then to use these organo-lipids in constructing the functionalized metal particle.
- M is the metal particle (either cluster or colloid of Au, Pt, Ag, Pd, and combinations), Or is an organic group of the organometallic particle (such as, phosphines containing linkable groups, polymers containing linkable groups, P(C 6 H 4 —CO—NH—(CH 2 ) 3 —NH 2 ) 3 , polyethyleneimine, polyacrylamide hydrazide, polylysine, etc.), and L is the lipid moiety.
- M is the metal particle (either cluster or colloid of Au, Pt, Ag, Pd, and combinations)
- Or is an organic group of the organometallic particle (such as, phosphines containing linkable groups, polymers containing linkable groups, P(C 6 H 4 —CO—NH—(CH 2 ) 3 —NH 2 ) 3 , polyethyleneimine, polyacrylamide hydrazide, polylysine, etc.)
- L is the lipid moiety.
- a novel gel stain product is a metal (preferably gold) cluster of the form described in #1 above using appropriate organic thiols.
- the thiols are preferably o-thiol benzoic acid, glutathione, and thioglucose, although others may be used.
- the general formula describing the product is: M k (SOr) m (SOr′) n . . . where M is the metal, S is sulfur, Or and Or′ are organic groups (such as proteins or nucleic acids containing thiols, most other organic thiols, glucose, benzoic acid, glutathione, cholesterol, etc.), and k, m and n are integers.
- the ellipsis indicates that one or more different (SOr) groups (organic thiols) may be attached per metal core.
- the process for a protein polyacrylamide gel is as follows: mix the organometallic particle with the protein sample with or without SDS (sodium dodecyl sulfate), for native or denaturing gels; if a reducing gel is desired, the protein is first reduced with a reductant, preferably ⁇ -mercaptoethanol, followed by a thiol blocking agent, preferably iodoacetamide, before adding the metal stain.
- the sample is heated briefly (e.g., one minute), loaded onto the gel and run normally.
- Stain development is effected by soaking the gel in a silver enhancement medium (e.g., AgNO 3 with hydroquinone) for several minutes followed by water or fixing washes.
- a silver enhancement medium e.g., AgNO 3 with hydroquinone
- the organometallic particles described above may be covalently incorporated into nucleic acids by several techniques. One is via synthesis of a metal particle attached to a nucleic acid base or analogue that has its other functional groups protected so that it is compatible with automated nucleic acids synthesis, such as use of phosphoramadite chemistry. A second approach is to incorporate appropriate organomettalic base analogs into nucleic acids enzymatically. A third method is to react activated organometallic clusters or colloids with functional groups incorporated into nucleic acids (such as primary amines). A fourth approach is to use organometallic particles that contain photoactive group(s) that then covalently attach to the nucleic acids when light activated.
- Tris (p-N-methylcarboxamidophenyl) phosphine in the ratio 2:1:5.
- the reaction mixture was extracted with 0.02M ammonium acetate with acetic acid, pH 5.8, in 20% isopropanol/water (3 ⁇ 150 mL), then evaporated to dryness, redissolved in DMSO (2 mL) and 0.6M triethylammonium bicarbonate in 20% isopropanol/water.
- the brownish-green product is the first species to be eluted. Yield was 820 mmol. UV/visible data suggested that the product incorporated 6 fluorescein groups per cluster.
- the orange-brown solution was added to 10 mL of aqueous 3.0M sodium chloride, stirred for 30 minutes, then evaporated to dryness, stirred with methanol (20 mL) and filtered through a medium porosity glass frit in order to exchange the coordinated cyanide ligands for chlorides.
- the cluster was separated from uncoordinated ligands and other smaller molecules by chromatography over a coarse gel filtration column (dimensions as described in the fluorescent Nanogold preparation) eluting with 0.6M triethylammonium bicarbonate buffer in 5% methanol/water.
- the pale greenish-orange cluster (yield close to 50 nmol) is eluted first, followed by uncoordinated ligands and smaller molecules.
- Nanogold was prepared as described for fluorescein-conjugated analog, except that a different mixture of phosphines was used to perform the ligand exchange on the freshly made compound.
- the protected cluster was isolated in the same manner as the fluorescein-conjugated analog.
- Nanogold 400 nmol of protected Nanogold was evaporated to dryness five times from methanol to remove triethylammonium bicarbonate, then dissolved in isopropanol (0.2 mL) and 0.1M sodium borate buffer, pH 9.0 (0.4 mL). This solution was added to a solution of Texas Red sulfonyl chloride (8-fold excess, 2.1 mg) in isopropanol (0.2 mL) and the mixture incubated at 4° C. for 1 hour.
- the dark blue product eluted in the void volume: it was evaporated to dryness from methanol five times, then the t-Boc protecting group was removed with 0.1M hydrochloric acid in methanol (1 hour).
- the solution was neutralized with triethylammonium buffer, evaporated to dryness and rechromatographed (GH25 gel, buffer as above) to remove triethylammonium chloride. Final yield was 170 nmol (43%). Labeling calculated from the UV/visible spectrum was 1.17 Texas Red groups per cluster.
- Fluorescein-conjugated Nanogold 250 nmol was evaporated to dryness five times from methanol solution to remove any triethylammonium bicarbonate, then dissolved in DMSO (0.5 mL) and 0.1M sodium phosphate buffer, pH 7.5 (0.9 mL) and added to a solution of a 100-fold excess of N-methoxycarbonylmaleimide (NMCM, 8 mg) in DMSO (0.1 mL), mixed and incubated at 0° C. for 30 minutes.
- [Au 11 -Fluorescein] labeling was conducted in the same manner, except that the buffer used to separate the activated fluorescein gold was prepared as a solution in 40% DMSO/water.
- Fluorescein-conjugated Nanogold 250 nmol was evaporated to dryness five times from methanol to remove any triethylammonium bicarbonate, then dissolved in DMSO (0.4 mL) and 0.02M HEPES-NaOH buffer, pH 7.5 (0.9 mL) and added to a solution of bis (sulfo-N-hydroxysuccinimidyl) suberate (BS 3 ) (250-fold excess: 38 mg) in DMSO (0.1 mL).
- the blue-grey product was the first species to be eluted.
- Cross-linking was performed with 1,1′-carbonyldiimidazole (CDI).
- CDI 1,1′-carbonyldiimidazole
- Hoescht-33258 (3 mg) was dissolved in 0.5 mL DMSO with a stoichiometric amount of CDI and incubated at room temperature for 30 minutes, then polyamino-1.4 nm gold cluster (150 nmol, giving 100-fold excess of dye) in DMSO (0.4 mL) was added and incubation continued for a further 1 hour at room temperature.
- the reaction mixture was then diluted with deionized water to 20% DMSO and concentrated three times to minimal volume using membrane centrifugation (10,000 MW cutoff).
- the solution was switched to a 30,000 MW cutoff membrane concentrator and centrifuged to minimal volume a further 8 times; no 1.4 nm gold was observed to pass through the membrane.
- the concentration of fluorescent dye in the filtrate was determined spectrophotometrically, and by the end of the eighth centrifugation had fallen to less than half the concentration of 1.4 nm gold particles remaining in the retained solution, diluted to the same volume.
- the ratio of dye molecules to gold clusters in the final product was estimated spectrophotometrically to be 1.2.
- Activation of the gold particles was conducted in methanol with a small amount of triethylamine added, until the reading of a pH meter inserted into the solution was between 7.5 and 8.0, to promote the reaction.
- 300 nmol of monoamino 1.4 nm gold, isolated by ion exchange chromatography (in 0.6M triethylammonium bicarbonate buffer in 20% isopropanol/water) was evaporated to dryness five times from methanol to remove the volatile buffer, then dissolved in 1.5 mL of triethylamine-treated methanol in which a 500-fold excess of bis(sulfo-succinimidyl) suberate (86 mg) was dissolved.
- the reaction mixture was evaporated to dryness, and stirred with 0.02M ammonium acetate, pH 5.80 (50 mL) to extract any unreacted Nanogold; this suspension was extracted three times with chloroform (15 mL).
- the combined chloroform extracts were evaporated to dryness, dissolved in a 2:1 methanol/chloroform mixture, and separated on a column identical to that used above for the Nanogold activation, eluted with the same solvent mixture.
- the dark brown Nanogold-DPPE conjugate is the first species to be eluted; unconjugated DPPE is eluted later.
- the brown DPPE conjugate is the first species to be eluted; colorless unreacted DPPE is eluted later.
- Both the activation reaction of the gold, and chromatographic separation of activated gold are conducted in a basic methanolic buffer, prepared as follows: sufficient HEPES to give 200 mL of a 0.02M solution (0.956 g) are suspended in methanol (200 mL), and triethylamine added slowly, dropwise, until all the HEPES is dissolved. A pH electrode was then inserted into the solution, and dilute triethylamine in methanol was added until the reading on the pH meter was between 7.6 and 8.0.
- Ion exchange-isolated monoamino undecagold (150 nmol, by UV/visible absorption spectroscopy, dissolved in aqueous 0.6M triethylammonium bicarbonate buffer in 5% methanol) was evaporated to dryness five times from ethanol to remove the volatile buffer. It was then dissolved in 0.6 mL of the methanolic HEPES buffer and added to a solution containing a 200-fold excess of bis(sulfosuccinimidyl) suberate (17 mg) in methanolic HEPES buffer (0.2 mL) to give a total volume of 0.8 mL. The solution was mixed thoroughly, then incubated at room temperature in a small polyethylene vial for 1 hour and 30 minutes.
- the activated undecagold cluster is the first species to be eluted.
- Fractions containing uncontaminated activated undecagold were pooled, to yield about 80 nmol of activated undecagold in 2 or 3 mL. This was then added to a solution of a 100-fold excess of DPPE (5.4 mg) in a volume of chloroform equal to one-half the volume of the activated undecagold (1 or 1.5 mL), mixed thoroughly, and incubated overnight at 4° C.
- the mixture was then evaporated to dryness, and shaken with a water/chloroform mixture to remove unreacted undecagold; the aqueous layer was removed and the process repeated twice.
- the organic layer and solid material accumulated at the phase boundary were then evaporated to dryness, dissolved in a 1:1 methanol/dichloromethane mixture (0.8 mL), and separated on a column identical to that used above to separate activated undecagold.
- the eluent was a 1:1 methanol/dichloromethane mixture.
- the Undecagold-DPPE conjugate is the first species to be eluted, and is orange in color; colorless unconjugated DPPE is eluted later.
- Monoamino-1.4 nm gold cluster is reacted in excess with alkyl acid chloride or alkyl acid anhydride in dichloromethane.
- the unreacted gold cluster was extracted from the reaction mixture into aqueous buffer and the product was purified from alkyl carboxylic acids, produced from the hydrolysis of unreacted acide derivatives, by size exclusion chromatography.
- the alkyl carboxylic acid derivatives include nonanoyl chloride, decanoyl chloride, decanoic anhydride, lauroyl chloride, lauric anhydride, palmitoyl chloride, palmitic anhydride, heptadecanoyl chloride, stearoyl chloride, and stearic anhydride.
- the contents of the reaction vessel were evaporated to dryness, and the greenish-black solid extracted with DMSO (0.5 mL) and 0.6M triethylammonium bicarbonate in 20% isopropanol/water (1.5 mL), filtered, then separated over a coarse gel filtration column (GH25, Amicon) eluting with 0.6M triethylammonium bicarbonate in 20% isopropanol/water. A dark greenish-brown compound was eluted in the void volume, and pale yellow species later. Electron microscopy of the greenish-brown compound showed metal particles 1-2 nm in diameter.
- F(ab′) 2 fragments or IgG molecules were reduced with 40 or 50 mM respectively mercaptoethylamine hydrochloride in 0.1M sodium phosphate buffer with 5 mM EDTA, pH 6.0, for 1 hour and 5 minutes at room temperature (in 1.5 mL volume).
- Reduced antibody was separated from excess mercaptoethylamine hydrochloride on a coarse gel filtration column (GH25, Amicon), eluting with 0.02 m sodium phosphate with 150 mM sodium chloride and 1 mM EDTA, pH 6.5; reduced antibody was eluted in the excluded volume.
- Platinum cluster (as isolated above; approximately one-third of the total isolated) was evaporated to dryness, then reevaporated to dryness five times from methanol solution to remove triethylammonium bicarbonate.
- the compound was then dissolved in DMSO (0.25 mL) and 0.1 m sodium phosphate, pH 7.5 (0.48 mL), and added to a solution of N-methoxycarbonylmaleimide (NMCM: 6 mg) in DMSO (0.07 mL); the solution was mixed thoroughly and incubated at 0° C. (ice bath/refrigerator) for 30 minutes.
- the activated platinum compound was then separated from excess smaller molecules on a coarse gel filtration column (GH25, Amicon), eluting with 0.02 m sodium phosphate with 150 mM NaCl and 1 mM EDTA in 20% DMSO/water; platinum-containing fractions were then added to those containing reduced antibody, mixed thoroughly and the mixture was incubated at 4° C. overnight.
- a coarse gel filtration column GH25, Amicon
- the reaction mixture was concentrated to between 0.5 and 1 mL (Centricon-30) and the products separated on a size fractionation column (Pharmacia Superose-12) eluted with 0.02 m sodium phosphate with 150 mM sodium chloride, pH 7.4; the first species to be eluted was greenish-brown in color and was in the position expected for antibody molecules.
- a size fractionation column Pharmacia Superose-12
- Fab′ conjugation is conducted using the same procedure used with the platinum cluster: F(ab′) 2 is first reduced and separated from excess reducing agent in the same manner. A suitable amount of the cluster is evaporated to dryness three times from methanol, with heating to 55°-60° C. to remove DMSO. The black solid is dissolved in DMSO (0.32 mL) and 0.1M sodium phosphate, pH 7.50 (0.40 mL) and added to a solution of N-methoxycarbonylmaleimide (NMCM: 6 mg) in DMSO (0.05 mL). The mixture is vortexed, incubated at 0° C. for 30 minutes (ice bath/refrigerator) then separated on a GH25 column. The activated cluster is eluted in the void volume: cluster-containing fractions are pooled and added to the reduced antibody. The mixture is left at room temperature for 1 hour, then stored at 4° C. overnight.
- Immunoblotting was conducted using a single-layer technique: mouse IgG was spotted onto a hydrated nitrocellulose membrane in serial dilutions, and detected using platinum or palladium labeled goat IgG and Fab′ anti-mouse IgG conjugates. Buffers required: PBS: 0.01M sodium phosphate with 150 mm sodium chloride, pH 7.4 WASH: 0.02M sodium phosphate with 150 mm sodium chloride, pH 7.4 0.8% w/w bovine serum albumin, fraction V by heat shock 0.1% w/w gelatin, type B from bovine skin, approximately 60 bloom 2 mM sodium azide.
- BLOCK- 0.02M sodium phosphate with 150 mm sodium chloride ING: pH 7.4 4.0% w/w bovine serum albumin, fraction V by heat shock. 0.1% w/w gelatin, type B from bovine skin, approximately 60 bloom 2 mM sodium azide.
- the last visible spot in a series of decreasing concentration contained 10 pg of mouse IgG for platinum-labeled goat Fab′- and IgG-anti-mouse IgG, and also for palladium-labeled goat anti-mouse Fab′.
- IgG conjugates this was the same level of sensitivity as was obtained from a second blot performed with the analogous Nanogold conjugate.
- KAuBr 4 8.418 ⁇ 10 ⁇ 3 mMol
- a mixed thiol solution of 3.62 mg of glutathione (1.18 ⁇ 10 ⁇ 2 mMol) and 1.10 mg of 1-thio-.beta.-D-Glucose (5.05 ⁇ 10 ⁇ 3 mMol) dissolved in 0.5 ml of distilled water is added to the KAuBr 4 solution in two 0.25 ml aliquots at 5 minute intervals. After the first addition the dark reddish brown KAuBr 4 solution turns to a clear, colorless to pale yellow solution.
- the reaction mixture is left for 5 minutes after the second addition of the mixed thiol solution.
- the pH of the reaction mixture is adjusted to 8 using 6N NaOH solution.
- Two 10 ⁇ L aliquots of NaBH 4 solution are added to the reaction mixture over 15 minutes.
- the pH is adjusted to neutral with 1N HCl solution, and a third 10 ⁇ L aliquots of NaBH 4 solution is added.
- the solution turns dark brown in color.
- the cluster is recovered from the void volume of the column. Cluster formation is verified by UV/VIS spectroscopy and electron microscopy.
- IgG 2 mg of IgG is combined in a siliconized microcentrifuge tube with 10 mg of mercaptoethanolamine in 1.4 ml of 0.1M sodium phosphate, pH 6.0 which contains 5 mM EDTA.
- the reaction is allowed to proceed 1 hour at room temperature, then the reduced antibody is separated from excess MEA on a GH-25 column (Amicon), eluting with 0.1M borate buffer, pH 9.2, with 5 mM EDTA.
- the reduced antibody is collected in the void volume of the column. Fractions are combined and reduced in volume to 0.1 ml with centricon-30 (Amicon). The reduced antibody fraction is then incubated at 37° C.
- reaction mixture is reduced in volume to 0.1 ml with centricon-30 (Amicon) and injected on a Superdex-75 molecular weight fractionation column (Pharmacia) to separate out the gold cluster-IgG conjugate from excess III.
- Antibody labelling is verified by UV/VIS spectroscopy and electron microscopy.
- F(ab′) 2 2 mg is combined in a siliconized microcentrifuge tube with 7 mg of mercaptoethanolamine in 1.4 ml of 0.1M sodium phosphate, pH 6.0 which contains 5 mM EDTA.
- the reaction is allowed to proceed 1 hour at room temperature, then the reduced antibody fragment is separated from excess MEA on a GH-25 column (Amicon), eluting with 0.1M borate buffer, pH 0.2, with 5 mM EDTA.
- the Fab′ fragment is collected in the void volume of the column. Fractions are combined and reduced in volume to 0.1 ml with centricon-30 (Amicon). The Fab′ fraction is then incubated at 37° C.
- the cluster is recovered from the void volume of the column.
- the cluster containing fractions are combined in a 50 ml round bottom flask and the solution is evaporated to dryness with a rotoevaporator (Buchi).
- the cluster is redissolved in methanol and re-evaporated with the rotoevaporator. This methanol evaporation is done 5 times.
- the cluster is then dissolved in 0.1 sodium phosphate buffer, pH 8.0, with 1.0 mM EDTA for use in subsequent protein staining experiments. Cluster formation is verified by UV/VIS spectroscopy and electron microscopy. As a thiol scavenger, an excess amount of N-ethylmaleimide is added to the cluster solution.
- KAuBr 4 8.41 ⁇ 10 ⁇ 3 mMol
- the precipitate is solubilized to give a clear, colorless to pale yellow solution.
- the reaction mixture is left for 5 minutes after the second addition of the mixed thiol solution.
- Two 10 ⁇ L aliquots of NaBH 4 solution are added to the reaction mixture over 15 minutes.
- the pH is adjusted to neutral with 1N HCl solution, and a third 10 ⁇ L aliquots of NaBH 4 solution is added.
- the solution turns dark brown in color.
- the cluster containing fractions are combined in a 50 ml round bottom flask and the solution is evaporated to dryness with a rotoevaporator (Buchi).
- the cluster is redissolved in methanol and re-evaporated with the rotoevaporator. This methanol evaporation is done 5 times.
- the cluster is then dissolved in 0.1 sodium phosphate buffer, pH 8.0, with 1.0 mM EDTA for use in subsequent protein staining experiments. Cluster formation is verified by UV/VIS spectroscopy and electron microscopy.
- a thiol scavenger an excess amount of N-ethylmaleimide is added to the cluster solution.
- Protein sample (Pharmacia LMW calibration kit proteins) to be analyzed is incubated with excess I or II in 10 mM Tris/HCl, 1 mM EDTA, pH 8.0. To the sample is added Sodium Dodecyl Sulphate (SDS) to 2.5%. The sample is heated for 5 minutes at 100° C. Bromophenol Blue is added to 0.01%.
- SDS Sodium Dodecyl Sulphate
- the gel is developed for 5-15 minutes (or until background development) with LI SILVER silver enhancement kit (Nanoprobes, Inc.). After silver development, gels are rinsed thoroughly with deionized water, and preserved by incubation in 20% glycerol in deionized water at 45° C. for 10 minutes.
- Protein sample (Pharmacia LMW calibration kit proteins) to be analyzed is incubated with a 2.5% mercaptosuccinic acid solution in 10 mM Tris/HCl, 1 mM EDTA, pH 8.0.
- SDS Sodium Dodecyl Sulphate
- the sample is heated for 5 minutes at 100° C.
- Bromophenol Blue is added to 0.01% and N-ethylmaleimide (prepared as a 20% solution in DMSO) is added to 5%.
- the sample is incubated at room temperature for 10 minutes. Excess amounts of I and II are added to the sample mixture.
- the gel is developed for 5-15 minutes (or until background development) with LI SILVER silver enhancement kit (Nanoprobes, Inc.). After silver development, gels are rinsed thoroughly with deionized water, and preserved by incubation in 20% glycerol in deionized water at 45° C. for 10 minutes.
- Oligonucleotides modified to contain biotin can be detected through the use of either gold cluster labeled anti-biotin antibodies, antibody fragments, gold cluster-labeled streptavidin, or gold cluster-labeled avidin. Incorporation of the biotin into an oligonucleotide strand can occur via a commercially available biotin-NHS reagent and a primary amine that was introduced onto the oligonucleotide via a modified nucleotide or nucleotide substitute (phosphoramidite) by a DNA synthesizer. The biotin labeled oligonucleotide can then be reacted with gold cluster labeled reagent designed to react with the biotin moiety and observed via silver development.
- biotin labeled oligonucleotides were reacted with streptavidin gold cluster conjugates in phosphate buffered saline (PBS), pH 7.4 for four hours at room temperature and separated by size exclusion chromatography (Superdex 75, nominal exclusion limit 70 kD) using the same buffer as eluant. On this column, the major peak coincided with the retention time of the cluster conjugate and showed enhanced absorption at 260 nm indicating reaction had occurred.
- PBS phosphate buffered saline
- the membrane After rinsing with buffer and then water, the membrane was treated with silver developer. The membrane was again rinsed with water and examined for spot generation after drying. The silver developed gold particle is seen as a dark spot.
- Another model system was the preparation of labeled complementary fragments to the single stranded phage M13mp18.
- biotin was introduced as modified dUTP and incorporated with Klenow.
- the biotinylated solution was applied to a nitrocellulose membrane, immobilized in a vacuum oven and detected by streptavidin gold cluster conjugate. In this procedure 10 ⁇ 15 mol M13mp18 was detected. The detection limit was independent of the concentration of the gold conjugate.
- Gold cluster labelled nucleotide triphosphate was prepared by reaction of NHS-gold cluster with an amino modified nucleotide triphosphate.
- the modified nucleotide was incorporated into an oligonucleotide by enzymatic extension of random primers.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Nanotechnology (AREA)
- Biophysics (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medical Informatics (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Analytical Chemistry (AREA)
- Condensed Matter Physics & Semiconductors (AREA)
- Materials Engineering (AREA)
- Inorganic Chemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Ceramic Engineering (AREA)
- High Energy & Nuclear Physics (AREA)
- Radiology & Medical Imaging (AREA)
Abstract
Small organometallic probes comprise a core of metal atoms bonded to organic moieties. The metal atoms are gold, silver, platinum, palladium, or combinations thereof. In one embodiment, a multifunctional organometallic probe comprises a core of metal atoms surrounded by a shell of organic moieties covalently attached to the metal atoms, a fluorescent molecule, e.g., fluorescein, covalently attached to one of the organic moieties, and a targeting molecule, e.g., an antibody, covalently attached to another of the organic moieties.
Description
- This application is a continuation of copending U.S. patent application Ser. No. 10/093,770, filed Mar. 8, 2002; which is a continuation-in-part of application Ser. No. 09/619,343, filed Jul. 19, 2000 and issued as U.S. Pat. No. 6,369,206; which is a divisional of application Ser. No. 09/039,601, filed Mar. 16, 1998 and issued as U.S. Pat. No. 6,121,425; which is a continuation-in-part of application Ser. No. 08/652,007, filed May 23, 1996 and issued as U.S. Pat. No. 5,728,590; which is a continuation-in-part of application Ser. No. 08/282,929, filed Jul. 29, 1994 and issued as U.S. Pat. No. 5,521,289.
- The present invention is directed to small organometallic probes, processes for making the small organometallic probes, and applications of the small organometallic probes. In particular, the small organometallic probes of the present invention are generally less than two microns (2 μm) across, and comprise a metal cluster compound having a solid metal core, with organic groups attached to the metal core. Alternatively, the organometallic probes may comprise a metal colloid having organic groups attached to the outer surface of the metal colloid. The metal clusters or colloids may also be functionalized with other molecules attached that can be used for targeting and detecting another substance, generally, a biologically significant substance, such as an antibody. The metal in the metal clusters or colloids is gold, platinum, silver, palladium or combinations thereof.
- Previous work by others has described the preparation of gold and silver colloids. Such colloids do not have a fixed number of metal atoms and vary considerably in size. For example, the metal colloids could vary in size from 1 nm to 2 μm in size and could contain from about 10 metal atoms to thousands of metal atoms, depending on size. It was found that a number of proteins, such as IgG antibodies, could be adsorbed to these sol particles. Gold colloids have been most commonly described. These conjugates have been used in electron and light microscopy as well as on immunodot blots for detection of target molecules. These conjugates have many shortcomings. Since the molecules are only adsorbed onto the colloids, they also desorb to varying extents. This leads to free antibody which competes for antigen sites and lowers targeting of gold. Furthermore, the shelf life of the conjugates is compromised by this problem. The ‘sticky’ colloids also tend to aggregate. If fluorescence is used to detect the target molecules, the gold particles quench most of it. Also, the gold colloids must be stabilized against dramatic aggregation or ‘flocculation’ when salts are added by adsorbing bulky proteins, such as bovine serum albumin. Due to the effects of aggregation and bulky additives, the penetration of immunoprobes into tissues is generally <0.5 μm. Accessibility of the probes to internal cell structures, e.g., nuclear proteins, or to cells deeper in a tissue sample, is impeded by these properties. Colloidal gold immunoprobes are also used in diagnosis on blots. The sensitivity of these detection schemes is again degraded by problems of aggregation, detachment of antibodies from the gold, and problems with shelf life. The gold prepared in standard ways also has low activity due to few adsorbed antibodies and denaturation of some antibodies during adsorption.
- Various metal cluster containing organic shells have also been previously described, such as Au11Ph7 (Ph=phenyl), Au25R (R=organic), Pd561, and others. These metal clusters have a fixed number of metal atoms in their metal cores which range in size from ca. 0.7-2.2 nm. Most of these metal clusters are based upon reduction of metal-triphenyl phosphines or the use of 1,10-phenanthroline.
- For example, Barlett, P. A. et al, in “Synthesis of Water-Soluble Undecagold Cluster Compounds . . . ,” J. Am. Chem. Soc., 100, 5085 (1978), describe a metal cluster compound (Au11) having a core of 11 gold atoms with a diameter of 0.8 nm. The metal core of 11 gold atoms in the undecagold metal cluster compound is surrounded by an organic shell of PAr3 groups. This metal cluster compound has been used to form gold immunoprobes, for example, by conjugating Au11 to Fab′ antibody fragments as well as other biological compounds.
- Another metal cluster compound which has been used as a probe is Nanogold™ available from the assignee of the present application. Nanogold™ has a metal core with 50-70 gold atoms (the exact number not yet being known but believed to be 67 gold atoms) surrounded by a similar shell of organic groups (PAr3) as undecagold. The metal core of Nanogold™ is 1.4 nm in diameter. The production of Nanogold is described in U.S. Pat. No. 5,360,895, of James F. Hainfeld and Frederic R. Furuya.
- Although the preparation and properties vary for these metal cluster compounds having organic shells, many of these can only be synthesized in low yields, derivatization for use in coupling to biomolecules is expensive in time and effort, and again in low yields, and many of the cluster compounds are degraded rapidly by heat or various chemical reagents.
- Briefly stated, the invention in a preferred form is a cluster complex or colloid including metal core particles and probe molecules covalently attached to the core particles. The probe molecules functionalize the cluster complex or colloid to target at least one other substance or to endow the particles with specified properties.
- The core particles are less than 2 microns in size and may be composed of gold, platinum, silver, palladium, or combinations thereof.
- The probe molecules may be covalently bonded to the core particles by a specific reaction of the probe molecules with a functional group incorporated into an outer surface of the core particle by means of chemical synthesis or modification. The functional group may be maleimide, N-hydroxysuccinimide, Sulfo-N-hydroxysuccinimide, aliphatic amine, 1,2-dihydroxy, aldehyde, nitrilotriaceitic acid (NTA) or its chelate with nickel, copper, iron, cobalt, or other transition metal.
- The probe molecules may be antibodies, antibody fragments, avidin or streptavidin, peptides, drugs, antigens, hormones, DNA, and RNA.
- The clusters or colloids may also include fluorescently labeled molecules covalently attached to the core particles, where the chemistry for covalently attaching the probe molecules and the fluorescently labeled molecules to the core particles controls the fluorophore of the fluorescently labeled molecules.
- The cluster complex or colloid may also include a polymer coating the core particles, the polymer being chosen from a group containing linear or branched polymer with functional groups, polyamino acids, polyethylene derivatives, and mixtures thereof.
- The invention is also a method for detecting a substance, where a sample suspected of containing the substance is mixed with a cluster complex or a colloid having metal core particles and probe molecules covalently attached to the core particles, the probe molecules functionalizing the cluster complex or colloid to target the substance.
- The method may include detecting the substance with a piezoelectric crystal mass measuring device, detecting the substance by using changes in reflected light from a surface, detecting the substance using light microscopy, detecting the substance using fluorescent microscopy, detecting the substance using confocal microscopy, or detecting the substance using electron microscopy.
- The method may include visualizing the localization or distribution of the substance within cells, tissue sections, organelles or organs using light microscopy, using fluorescent microscopy, or using confocal microscopy, using electron microscopy.
- The method may include detecting the substance using both light, fluorescence or confocal microscopy and electron microscopy, the cluster complex or colloid also including fluorescently labeled molecules covalently attached to the core particles, where the chemistry for covalently attaching the probe molecules and the fluorescently labeled molecules to the core particles controls the fluorophore of the fluorescently labeled molecules.
- The method may include visualizing the localization or distribution of the substance within cells, tissue sections, organelles or organs using both light, fluorescence or confocal microscopy and electron microscopy, the cluster complex or colloid also including fluorescently labeled molecules covalently attached to the core particles, where the chemistry for covalently attaching the probe molecules and the fluorescently labeled molecules to the core particles controls the fluorophore of the fluorescently labeled molecules.
- Other objects and advantages of the invention will become apparent from the drawings and specification.
- 1. “Thiol gold clusters” are novel gold clusters produced by a novel synthesis. The procedure is: form an organic-gold complex by reacting a compound containing a thiol with gold in solution. A second equivalent is also added of the thiol compound. Finally the gold organic is reduced with NaBH4 or other reducing agents and organometallic particles are formed. These have the general formula AunRmR′i . . . , where n, m, and l are integers, R and R′ are organic thiols, (e.g., alkyl thiols, aryl thiols, proteins containing thiol, peptides or nucleic acids with thiol, glutathione, cysteine, thioglucose, thiol benzoic acid, etc.) and the ellipsis indicates that one or more organic thiols may be used. With two equivalents of organic thiol compound, clusters with gold cores ˜1.4 nm are formed with many organics. The organic moiety may then be reacted by usual reactions to covalently link this particle to antibodies, lipids, carbohydrates, nucleic acids, or other molecules to form probes. Mixtures of organic thiols may be used to provide mixed functionality to the clusters. These organo-gold clusters are stable to heating at 100° C.
- 2. The thiol-gold preparation described in #1 above may be altered such that a larger molar ratio of organic thiol to gold is used. Ratios above approximately 2:1 or below 1:2 result in organic-gold colloids whose size depends on this ratio. These are useful when large gold particles are desired.
- 3. The organic thiol-gold preparations described in #'s 1 and 2 above may be made using a similar process with alternatives metals to gold, e.g., platinum, silver, palladium and other metals.
- 4. The organic thiol-metal particles described in #'s 1, 2, and 3 above may be made using mixtures of metal ions, e.g., gold and silver, resulting in mixed metal clusters.
- 5. A novel process has been developed for coating colloidal particles (of various types including gold, silver, and other metals) with organic moieties having groups suitable for covalently attaching additional molecules, such as antibodies, nucleic acids, lipids, peptides, and other proteins. The process consists of synthesizing the metal colloid in the presence of a suitable polymer, e.g., HAuCl4 (0.01%) in 0.05M sodium hydrogen maleate buffer (pH 6.0), with 0.004% tannic acid. The polymer may be chosen from a linear or branched group with functional groups attached, such as polyamino acids, polyethylene derivatives, other polymers, or mixtures thereof. Optimal molecular weight of the polymer varies with the specific ones chosen. A second method is to synthesize the metal particle first, e.g., by combining 0.01% HAuCl4 with 1% sodium citrate with heating. Once gold colloid is formed of the desired size, it is coated with one of the above polymers by mixing the two together and optionally warming to 60°-100° C. for several minutes. The polymer coating may be further stabilized by a) microwave heating, b) further chemical crosslinking, e.g., by glutaraldehyde or other linkers, or by continued polymerization adding substrate molecules for a brief period. Use of N, N′-methylene bis acrylamide, for example, can covalently further stabilize the polymer coating. Photocrosslinking may also be used.
- The functionalized polymer coating may now be used to covalently attach proteins, peptides, antibodies, lipids, carbohydrates, nucleic acids, drugs, hormones, or other substances. This has the advantage that this step may be done mildly, in physiological buffers if desired, using standard crosslinking technology. This eliminates the usual restriction that conjugation must be performed in very low ionic strength buffers, which precludes attachment of certain molecules such as many IgM's which cannot withstand the low ionic strength requirement.
- 6. Combined (bifunctional) fluorescent and metal particle probes have been synthesized that have the formula: Mn(OrF)m(Or′T)l(Or″)p, where M is a metal core consisting of multiple metal atoms (Au, Pt, Ag, Pd) that can be mixed, covalently bonded to a shell of organic groups (Or, Or′, and Or″). Or and Or″ are organic coupling moieties, (e.g., triphenyl phosphines 1,10 phenanthrolines, triphenyl phosphines or phenanthrolines containing linkable groups such as amines or carboxyls, triphenyl phosphines or 1,10 phenanthrolines containing reactive groups such as maleimides or N-hydroxysuccinimide esters, P(C6H4—CO—NH—(CH2)3—NH2)3, P(C6H4—CO—NH—CH3)2(C6H4—CO—NH—(CH2)3—NH2), P(C6H4—CO—N H—(CH2)3—NC4O2H2)3, P(C6H4—CO—NH—(CH2)3—NH—(CH2)6—CO2—NC4O2H4)3, etc.), Or″ is an organic group (e.g., triphenyl phosphines, 1,10 phenanthrolines, P(C6H4—CHOH—CH2OH)3, P(C6H4—CO—NH—CH3)3, P(C6H5)3, P(C6H4SO3)3, etc.), part of the metal cluster, F is a fluorescent molecule, (e.g., fluorescein, rhodamine, aminomethyl coumarin, Texas Red, etc.) and T is an optional targeting molecule such as antibody, peptide, drug, etc. Or, Or′, and Or″ may be the same or different. The subscripts 1, n, m and p indicate that multiple copies of each moiety are possible and include mixtures of different metals, fluorescent groups, organic groups and targeting molecules for multifunctional conjugates. A specific example of this is: Au11[Pph(CONHCH3)]6 phCONH(CH2)3 NH—F, where ph is a phenyl group, and F is a fluorescent molecule.
- A process to produce such multifunctional metal particles is as follows: a metal cluster or metal colloid is synthesized having one or more reactive groups such as an amine or carboxyl. These are then reacted to covalently link a fluorescent molecule molecule such as fluorescein, Texas Red, rhodamine, or aminomethyl coumarin, and optionally a targeting or other molecule is covalently attached such as an antibody or antibody fragment, a peptide, streptavidin, or other proteins, a nucleic acid (RNA or DNA), drugs, hormones, or other molecules. Alternatively, the fluorescent groups may be incorporated into ligands which are then used to prepare the cluster.
- 7. Lipid molecules (fatty acids, phospholipids, or others) are covalently attached to metal particles (clusters or coated reactive colloids). This process uses a reactive lipid derivative, e.g., a sulfonyl chloride or anhydride, which is reacted with an amino group, for example, on the metal particle. Alternatively, organic groups on the metal particle or lipid may be reacted with bifunctional crosslinkers which are then reacted with the other species. Another process is to presynthesize the organic components of the metal particles (e.g., phosphines or polymers) with lipid molecules attached and then to use these organo-lipids in constructing the functionalized metal particle.
- The general formula for the product is:
M-Or-L
where M is the metal particle (either cluster or colloid of Au, Pt, Ag, Pd, and combinations), Or is an organic group of the organometallic particle (such as, phosphines containing linkable groups, polymers containing linkable groups, P(C6H4—CO—NH—(CH2)3—NH2)3, polyethyleneimine, polyacrylamide hydrazide, polylysine, etc.), and L is the lipid moiety. - 8. A novel gel stain product is a metal (preferably gold) cluster of the form described in #1 above using appropriate organic thiols. The thiols are preferably o-thiol benzoic acid, glutathione, and thioglucose, although others may be used. The general formula describing the product is:
Mk(SOr)m(SOr′)n . . .
where M is the metal, S is sulfur, Or and Or′ are organic groups (such as proteins or nucleic acids containing thiols, most other organic thiols, glucose, benzoic acid, glutathione, cholesterol, etc.), and k, m and n are integers. The ellipsis indicates that one or more different (SOr) groups (organic thiols) may be attached per metal core. - The process for a protein polyacrylamide gel is as follows: mix the organometallic particle with the protein sample with or without SDS (sodium dodecyl sulfate), for native or denaturing gels; if a reducing gel is desired, the protein is first reduced with a reductant, preferably β-mercaptoethanol, followed by a thiol blocking agent, preferably iodoacetamide, before adding the metal stain. The sample is heated briefly (e.g., one minute), loaded onto the gel and run normally. Stain development is effected by soaking the gel in a silver enhancement medium (e.g., AgNO3 with hydroquinone) for several minutes followed by water or fixing washes.
- 9. The organometallic particles described above may be covalently incorporated into nucleic acids by several techniques. One is via synthesis of a metal particle attached to a nucleic acid base or analogue that has its other functional groups protected so that it is compatible with automated nucleic acids synthesis, such as use of phosphoramadite chemistry. A second approach is to incorporate appropriate organomettalic base analogs into nucleic acids enzymatically. A third method is to react activated organometallic clusters or colloids with functional groups incorporated into nucleic acids (such as primary amines). A fourth approach is to use organometallic particles that contain photoactive group(s) that then covalently attach to the nucleic acids when light activated.
- The invention will further be described by reference to specific examples.
- Preparation of Fluorescent and Gold Immunoprobes
- 1. Preparation of Fluorescein-Conjugated Nanoqold Using Fluorescein-Pbosphine
- A tris (aryl) phosphine ligand bearing a single fluorescein substitutent, and a second tris (aryl) phosphine ligand bearing a single primary amine, were mixed with tris (p-N-methylcarboxamidophenyl) phosphine in the ratio 2:1:5. Ninety mg of this ligand mixture in 25 mL of methanol (an estimated twelve-fold molar excess) was added to a solution of freshly prepared Nanogold (product from 0.4 g of gold (I) triphenylphosphine chloride) in dichloromethane (25 mL) and stirred at room temperature overnight.
- The reaction mixture was extracted with 0.02M ammonium acetate with acetic acid, pH 5.8, in 20% isopropanol/water (3×150 mL), then evaporated to dryness, redissolved in DMSO (2 mL) and 0.6M triethylammonium bicarbonate in 20% isopropanol/water. The fluorescein-substituted Nanogold was isolated by gel filtration, using a coarse gel in a large column (length=120 cm, internal diameter=2.5 cm, volume=590 mL), eluting with 0.6M triethylammonium bicarbonate in 20% isopropanol/water. The brownish-green product is the first species to be eluted. Yield was 820 mmol. UV/visible data suggested that the product incorporated 6 fluorescein groups per cluster.
- 2. Preparation of Fluorescein-Conjugated Undecagold Using Fluorescein-Phosphine
- Gold (I) cyanide (31 mg, 0.14 mmol) was stirred with a 4:1:1 mixture of a tris (aryl) phosphine ligand bearing a single fluorescein substitutent, a second tris (aryl) phosphine ligand bearing a single primary amine, and tris (p-N-methylcarboxamidophenyl) phosphine (105 mg, 0.14 mmol) in a mixture of methanol (3 mL) and ethanol (5 mL) for 4 hours. Sodium borohydride (3 mg, 0.1 mmol) in ethanol (2.0 mL) was added dropwise over 30 minutes, then 8 drops of acetone were added to stop the reduction. The orange-brown solution was added to 10 mL of aqueous 3.0M sodium chloride, stirred for 30 minutes, then evaporated to dryness, stirred with methanol (20 mL) and filtered through a medium porosity glass frit in order to exchange the coordinated cyanide ligands for chlorides.
- The cluster was separated from uncoordinated ligands and other smaller molecules by chromatography over a coarse gel filtration column (dimensions as described in the fluorescent Nanogold preparation) eluting with 0.6M triethylammonium bicarbonate buffer in 5% methanol/water. The pale greenish-orange cluster (yield close to 50 nmol) is eluted first, followed by uncoordinated ligands and smaller molecules. Calculations based on the UV/visible absorption spectrum suggested incorporation of 5.5 fluorescein groups per undecagold.
- 3. Preparation of Texas Red-Conjugated Nanogold
- Nanogold was prepared as described for fluorescein-conjugated analog, except that a different mixture of phosphines was used to perform the ligand exchange on the freshly made compound. A 2:1:8 mixture of a phosphine bearing a single primary amine, a phosphine containing a single primary amine protected with a t-Boc group, and tris (p-N-methylcarboxamidophenyl) phosphine. The protected cluster was isolated in the same manner as the fluorescein-conjugated analog.
- 400 nmol of protected Nanogold was evaporated to dryness five times from methanol to remove triethylammonium bicarbonate, then dissolved in isopropanol (0.2 mL) and 0.1M sodium borate buffer, pH 9.0 (0.4 mL). This solution was added to a solution of Texas Red sulfonyl chloride (8-fold excess, 2.1 mg) in isopropanol (0.2 mL) and the mixture incubated at 4° C. for 1 hour. The products were separated by coarse gel filtration (GH25 gel, Amicon, using column with length=50 cm, internal diameter=0.66 cm, volume=16 mL) eluting with 0.6M triethylammonium bicarbonate in 50% isopropanol/water. The dark blue product eluted in the void volume: it was evaporated to dryness from methanol five times, then the t-Boc protecting group was removed with 0.1M hydrochloric acid in methanol (1 hour). The solution was neutralized with triethylammonium buffer, evaporated to dryness and rechromatographed (GH25 gel, buffer as above) to remove triethylammonium chloride. Final yield was 170 nmol (43%). Labeling calculated from the UV/visible spectrum was 1.17 Texas Red groups per cluster.
- 4. Conjugation of Fluorescein-Nanoqold or Undecaqold to Antibody Fab′ Fragments
- F(ab′)2 antibody fragments (1.0 mg) were reduced with 40 mM mercaptoethylamine hydrochloride in 0.1M sodium phosphate at pH 6.0, with 5 mM EDTA (1.4 mL) for 1 hour at room temperature. Then the Fab′ fragments were separated on a coarse gel filtration column (GH25, Amicon: length=50 cm, internal diameter=1.0 cm, volume=40 mL), and eluted with 0.02M sodium phosphate, pH 6.5, with 150 mM NaCl and 1 mM EDTA.
- Fluorescein-conjugated Nanogold (250 nmol) was evaporated to dryness five times from methanol solution to remove any triethylammonium bicarbonate, then dissolved in DMSO (0.5 mL) and 0.1M sodium phosphate buffer, pH 7.5 (0.9 mL) and added to a solution of a 100-fold excess of N-methoxycarbonylmaleimide (NMCM, 8 mg) in DMSO (0.1 mL), mixed and incubated at 0° C. for 30 minutes. Maleimido-[Nanogold-fluorescein] was separated from unreacted NMCM on a coarse gel filtration column (GH25, Amicon: length=50 cm, internal diameter=1.0 cm, volume=40 mL), eluted with 0.02M sodium phosphate, pH 6.5, with 150 mM NaCl and 1 mM EDTA in 10% isopropanol/water. Maleimido-[Nanogold-fluorescein] was eluted in the excluded volume; a 5-fold excess was added to the Fab′ fragments and the mixture mixed and incubated at 4° C. overnight. The product was concentrated to 0.5 mL using centrifuge membrane concentrators with a 30,000 molecular weight cutoff (Centricon-30, Amicon), then isolated by gel filtration chromatography using a medium gel (Amicon GCL-90: Column length=50 cm, internal diameter=0.66 cm, volume=16 mL). 0.02M sodium phosphate with 150 mM sodium chloride, pH 7.40, was used as the eluent. The labeled Fab′ fragments eluted first, followed by unbound fluorescein-Nanogold. The process was repeated once for highest purity of product.
- [Au11-Fluorescein] labeling was conducted in the same manner, except that the buffer used to separate the activated fluorescein gold was prepared as a solution in 40% DMSO/water.
- 5. Labeling of Streptavidin with Fluorescein-Conjugated Nanoqold
- Fluorescein-conjugated Nanogold (250 nmol) was evaporated to dryness five times from methanol to remove any triethylammonium bicarbonate, then dissolved in DMSO (0.4 mL) and 0.02M HEPES-NaOH buffer, pH 7.5 (0.9 mL) and added to a solution of bis (sulfo-N-hydroxysuccinimidyl) suberate (BS3) (250-fold excess: 38 mg) in DMSO (0.1 mL). The solution was mixed thoroughly, incubated at room temperature for 1 hour and 25 minutes, then sulfo-NHS-[Fluorescein-Nanogold] was separated from excess (BS3) by chromatography on a coarse gel filtration column (GH25, Amicon: length=50 cm, internal diameter=1.0 cm, volume=40 mL), eluting with 0.02M HEPES-NaOH, pH 7.5, in 20% isopropanol/water. Activated fluorescein-Nanogold was the first species to be eluted, and was mixed in 12-fold excess to a solution of streptavidin in an aqueous solution of the same buffer. The mixture was incubated at 4° C. overnight, then reduced to 0.5 mL by membrane centrifugation (Centricon-30, Amicon) and purified twice by gel filtration (Amicon GCL-90 gel: Column length=50 cm, internal diameter=0.66 cm, volume=16 mL) eluted with 0.02M sodium phosphate buffer, pH 7.4 with 150 mM NaCl. Labeled streptavidin is the first species to be eluted.
- Labeling of Antibody Fab′ Fragments with Texas Red-Conjugated Nanogold
- Antibody reduction and fluorescent gold label conjugation were conducted as described for fluorescein-Nanogold. Texas Red-Nanogold (200 nmol) was converted to the maleimide form by reaction with a 100-fold excess of NMCM (3 mg) for 30 minutes at 0° C. in DMSO (0.30 mL), and 0.1M sodium phosphate buffer at pH 7.5 (0.45 mL); the activated label was isolated by chromatography over a coarse gel filtration column (GH25, Amicon: length=50 cm, internal diameter=0.66 cm, volume=16 mL), eluted with 0.02M sodium phosphate with 150 mM sodium chloride and 1 MM EDTA in isopropanol/water; gold-containing fractions were added in fivefold excess to Fab′ fragments, prepared from F(ab′) fragments as described in Example 3, and incubated at 2°-8° C. overnight. The product was isolated on a medium gel filtration column (Amicon GCL-90: 50 cm, internal diameter=0.66 cm, volume=16 mL), eluting with 0.02 P 7.4+150 mm NaCl. The blue-grey product was the first species to be eluted.
- 7. Conjugation of Hoescht-33258 to Nanogold
- Cross-linking was performed with 1,1′-carbonyldiimidazole (CDI). Hoescht-33258 (3 mg) was dissolved in 0.5 mL DMSO with a stoichiometric amount of CDI and incubated at room temperature for 30 minutes, then polyamino-1.4 nm gold cluster (150 nmol, giving 100-fold excess of dye) in DMSO (0.4 mL) was added and incubation continued for a further 1 hour at room temperature. The reaction mixture was then diluted with deionized water to 20% DMSO and concentrated three times to minimal volume using membrane centrifugation (10,000 MW cutoff). The solution was switched to a 30,000 MW cutoff membrane concentrator and centrifuged to minimal volume a further 8 times; no 1.4 nm gold was observed to pass through the membrane. The concentration of fluorescent dye in the filtrate was determined spectrophotometrically, and by the end of the eighth centrifugation had fallen to less than half the concentration of 1.4 nm gold particles remaining in the retained solution, diluted to the same volume. The ratio of dye molecules to gold clusters in the final product was estimated spectrophotometrically to be 1.2.
- Preparation of Gold-Labeled Dipalmitoyl Phosphatidyl Ethanolamine (DPPE)
- 8. Labeling of DPPE with Freshly Activated 1.4 nm Gold
- Activation of the gold particles was conducted in methanol with a small amount of triethylamine added, until the reading of a pH meter inserted into the solution was between 7.5 and 8.0, to promote the reaction. 300 nmol of monoamino 1.4 nm gold, isolated by ion exchange chromatography (in 0.6M triethylammonium bicarbonate buffer in 20% isopropanol/water) was evaporated to dryness five times from methanol to remove the volatile buffer, then dissolved in 1.5 mL of triethylamine-treated methanol in which a 500-fold excess of bis(sulfo-succinimidyl) suberate (86 mg) was dissolved. This mixture was incubated at room temperature for 1 hour 30 minutes. The activated 1.4 nm gold was separated over a coarse gel filtration column (Amicon, GH25: length=50 cm, internal diameter=1.0 cm, volume=40 mL), eluted with methanol; the dark brown activated Nanogold is the first species to elute. Fractions containing uncontaminated activated Nanogold were combined to yield 180 nmol of activated gold, in 4 or 6 mL. A solution of DPPE (100-fold excess: 12 mg) in one-half this volume of trichloromethane was added and the mixture incubated at 4° C. overnight.
- The reaction mixture was evaporated to dryness, and stirred with 0.02M ammonium acetate, pH 5.80 (50 mL) to extract any unreacted Nanogold; this suspension was extracted three times with chloroform (15 mL). The combined chloroform extracts were evaporated to dryness, dissolved in a 2:1 methanol/chloroform mixture, and separated on a column identical to that used above for the Nanogold activation, eluted with the same solvent mixture. The dark brown Nanogold-DPPE conjugate is the first species to be eluted; unconjugated DPPE is eluted later.
- 9. Labeling of DPPE with Lyophilized Mono-Sulfo-NHS-1.4 nm Gold (Nanogold)
- 60 nmol of lyophilized monofunctional sulfo-NHS-Nanogold (Nanoprobes, catalog number 2025: two vials) was redissolved in methanol (2 mL) with a drop of triethylamine, and added to a 150-fold excess of DPPE in a 2:1 methanol/chloroform mixture with a small amount of dichloromethane (4 mL), mixed thoroughly and incubated overnight at 4° C.
- The reaction mixture was evaporated to dryness, then redissolved in a 2:1 methanol/chloroform mixture (0.8 mL), filtered, and chromatographed over a coarse gel filtration column (Amicon GH25: length=50 cm, internal diameter=0.66 cm, volume=16 mL), eluting with 2:1 methanol:trichloromethane. The brown DPPE conjugate is the first species to be eluted; colorless unreacted DPPE is eluted later.
- 10. Preparation of Undecagold-DPPE
- Both the activation reaction of the gold, and chromatographic separation of activated gold, are conducted in a basic methanolic buffer, prepared as follows: sufficient HEPES to give 200 mL of a 0.02M solution (0.956 g) are suspended in methanol (200 mL), and triethylamine added slowly, dropwise, until all the HEPES is dissolved. A pH electrode was then inserted into the solution, and dilute triethylamine in methanol was added until the reading on the pH meter was between 7.6 and 8.0.
- Ion exchange-isolated monoamino undecagold (150 nmol, by UV/visible absorption spectroscopy, dissolved in aqueous 0.6M triethylammonium bicarbonate buffer in 5% methanol) was evaporated to dryness five times from ethanol to remove the volatile buffer. It was then dissolved in 0.6 mL of the methanolic HEPES buffer and added to a solution containing a 200-fold excess of bis(sulfosuccinimidyl) suberate (17 mg) in methanolic HEPES buffer (0.2 mL) to give a total volume of 0.8 mL. The solution was mixed thoroughly, then incubated at room temperature in a small polyethylene vial for 1 hour and 30 minutes. Activated undecagold was separated from excess BS3 using a coarse gel filtration column (Amicon GH25; length=50 cm, internal diameter=0.66 cm; volume=16 mL), eluting with methanolic HEPES buffer prepared earlier. The activated undecagold cluster is the first species to be eluted. Fractions containing uncontaminated activated undecagold were pooled, to yield about 80 nmol of activated undecagold in 2 or 3 mL. This was then added to a solution of a 100-fold excess of DPPE (5.4 mg) in a volume of chloroform equal to one-half the volume of the activated undecagold (1 or 1.5 mL), mixed thoroughly, and incubated overnight at 4° C.
- The mixture was then evaporated to dryness, and shaken with a water/chloroform mixture to remove unreacted undecagold; the aqueous layer was removed and the process repeated twice. The organic layer and solid material accumulated at the phase boundary were then evaporated to dryness, dissolved in a 1:1 methanol/dichloromethane mixture (0.8 mL), and separated on a column identical to that used above to separate activated undecagold. The eluent was a 1:1 methanol/dichloromethane mixture. The Undecagold-DPPE conjugate is the first species to be eluted, and is orange in color; colorless unconjugated DPPE is eluted later.
- Preparation of Alkylamido-1.4 nm Gold Cluster Derivatives
- General:
- Monoamino-1.4 nm gold cluster is reacted in excess with alkyl acid chloride or alkyl acid anhydride in dichloromethane. The unreacted gold cluster was extracted from the reaction mixture into aqueous buffer and the product was purified from alkyl carboxylic acids, produced from the hydrolysis of unreacted acide derivatives, by size exclusion chromatography. The alkyl carboxylic acid derivatives include nonanoyl chloride, decanoyl chloride, decanoic anhydride, lauroyl chloride, lauric anhydride, palmitoyl chloride, palmitic anhydride, heptadecanoyl chloride, stearoyl chloride, and stearic anhydride.
- 11. 300 nmol of monoamino 1.4 nm gold cluster, isolated by ion exchange chromotography and removal of volatile buffer salts by evaporation, was placed in 3 ml dichloromethane and treated with 200 nmol palmitoyl chloride. The mixture was stirred for 1 hour and then washed three times with 0.1M sodium phosphate buffer pH 6.5. The remaining reaction mixture was evaporated to dryness, redissolved in a 2:1 methanol/chloroform, and separated on a gel filtration column (Amicon GH25) eluting with 2:1 methanol/chloroform. The first to elute is the dark brown palmitamido gold cluster.
- Preparation of Large Platinum and Palladium Cluster Immunoprobes
-
- From platinum (II) acetylacetonate and bathophenanthroline: A mixture of Pt11(acac)2 (0.20 g, 0.5 mmol), bathophenanthroline (1:35 mg, 0.064 mmol) and 5-10:1 mixed ligand (3:5 mg, 0,016 mmol) was stirred in glacial acetic acid (20 mL) under a slow flow of nitrogen. Meanwhile sodium borohydride (2.3 g) was dissolved in 2-methoxyethyl ether (diglyme: 30 mL) and a 1:1 mixture of ethanol/water (20 mL) was added dropwise over 30 minutes; the hydrogen generated from this solution was bubbled into the reaction mixture. After 30 minutes no color change was observed: therefore, a small amount of platinum (II) chloride (˜0.05 g) suspended in acetic acid (1 mL) was added and stirring continued. H2 bubbling was continued for a further 4 hours, during which time the solution darkened from yellow to green and a greenish-black precipitate was formed. The solution was then aerated for 2 hours by blowing air into the flask.
- The contents of the reaction vessel were evaporated to dryness, and the greenish-black solid extracted with DMSO (0.5 mL) and 0.6M triethylammonium bicarbonate in 20% isopropanol/water (1.5 mL), filtered, then separated over a coarse gel filtration column (GH25, Amicon) eluting with 0.6M triethylammonium bicarbonate in 20% isopropanol/water. A dark greenish-brown compound was eluted in the void volume, and pale yellow species later. Electron microscopy of the greenish-brown compound showed metal particles 1-2 nm in diameter.
- From Platinum (II) chloride and substituted phenanthrolines: A mixture of platinum (II) chloride (0.5 mmol, 126 mg), ligands 2 (14.8 mg) and 3 (5.1 mg) were stirred in glacial acetic acid (25 mL) for 6 hours and heated to 100° C. to partially dissolve the solids. After cooling to room temperature overnight, hydrogen (generated as described above) was bubbled slowly through the reaction mixture for 3 hours; the color darkened from brown to greenish-black. The reaction mixture was then poured into a glass beaker and stirred overnight while air was bubbled through the solution. All the acetic acid was removed to leave a greenish black solid. This was then extracted into DMSO (0.5 mL) and 0.6M triethylammonium bicarbonate in 20% DMSO/water (1.5 mL), filtered, and separated on a coarse gel filtration column (GH25, Amicon) eluting with 0.6M triethylammonium bicarbonate in 20% DMSO/water. A brownish-green species was eluted in the void volume.
- 13. Conjugation of Functionalized Platinum Cluster to Antibodies
- F(ab′)2 fragments or IgG molecules were reduced with 40 or 50 mM respectively mercaptoethylamine hydrochloride in 0.1M sodium phosphate buffer with 5 mM EDTA, pH 6.0, for 1 hour and 5 minutes at room temperature (in 1.5 mL volume). Reduced antibody was separated from excess mercaptoethylamine hydrochloride on a coarse gel filtration column (GH25, Amicon), eluting with 0.02 m sodium phosphate with 150 mM sodium chloride and 1 mM EDTA, pH 6.5; reduced antibody was eluted in the excluded volume.
- Platinum cluster (as isolated above; approximately one-third of the total isolated) was evaporated to dryness, then reevaporated to dryness five times from methanol solution to remove triethylammonium bicarbonate. The compound was then dissolved in DMSO (0.25 mL) and 0.1 m sodium phosphate, pH 7.5 (0.48 mL), and added to a solution of N-methoxycarbonylmaleimide (NMCM: 6 mg) in DMSO (0.07 mL); the solution was mixed thoroughly and incubated at 0° C. (ice bath/refrigerator) for 30 minutes. The activated platinum compound was then separated from excess smaller molecules on a coarse gel filtration column (GH25, Amicon), eluting with 0.02 m sodium phosphate with 150 mM NaCl and 1 mM EDTA in 20% DMSO/water; platinum-containing fractions were then added to those containing reduced antibody, mixed thoroughly and the mixture was incubated at 4° C. overnight.
- Next day, the reaction mixture was concentrated to between 0.5 and 1 mL (Centricon-30) and the products separated on a size fractionation column (Pharmacia Superose-12) eluted with 0.02 m sodium phosphate with 150 mM sodium chloride, pH 7.4; the first species to be eluted was greenish-brown in color and was in the position expected for antibody molecules. In the Fab′ preparations, fractions comprising this peak were concentrated and re-chromatographed on a Superdex-75 column in the same buffer. The first species to emerge was the antibody conjugate; some resolution of unlabeled from labeled Fab′ fragments was observed.
- 14. Preparation and Antibody Conjugation of Functionalized 2-3 nm Pd Cluster
- Palladium (II) acetate (1.0 mmol, 227 mg), and a mixture of ligands 2 (27 mg) and 3 (8.5 mg) were stirred in glacial acetic acid (25 mL) with stirring under a slow stream of nitrogen. The mixture was warmed to 80° C. to dissolve all the components, to give an orange-brown solution. After cooling to room temperature hydrogen (generated as described above) was bubbled slowly through the mixture for 3 hours to give a near-black solution. This was stirred in a glass beaker under a stream of air until dry, then dissolved in DMSO (1.0 mL) and 0.6M triethylammonium bicarbonate in 20% DMSO/water (3.0 mL), filtered, and separated on a coarse gel filtration column (GH25, Amicon) eluting with 0.6M triethylammonium bicarbonate in 20% DMSO/water. The cluster was eluted in the exclusion volume.
- Fab′ conjugation is conducted using the same procedure used with the platinum cluster: F(ab′)2 is first reduced and separated from excess reducing agent in the same manner. A suitable amount of the cluster is evaporated to dryness three times from methanol, with heating to 55°-60° C. to remove DMSO. The black solid is dissolved in DMSO (0.32 mL) and 0.1M sodium phosphate, pH 7.50 (0.40 mL) and added to a solution of N-methoxycarbonylmaleimide (NMCM: 6 mg) in DMSO (0.05 mL). The mixture is vortexed, incubated at 0° C. for 30 minutes (ice bath/refrigerator) then separated on a GH25 column. The activated cluster is eluted in the void volume: cluster-containing fractions are pooled and added to the reduced antibody. The mixture is left at room temperature for 1 hour, then stored at 4° C. overnight.
- 15. Immunoblotting of Conjugates
- Immunoblotting was conducted using a single-layer technique: mouse IgG was spotted onto a hydrated nitrocellulose membrane in serial dilutions, and detected using platinum or palladium labeled goat IgG and Fab′ anti-mouse IgG conjugates.
Buffers required: PBS: 0.01M sodium phosphate with 150 mm sodium chloride, pH 7.4 WASH: 0.02M sodium phosphate with 150 mm sodium chloride, pH 7.4 0.8% w/w bovine serum albumin, fraction V by heat shock 0.1% w/w gelatin, type B from bovine skin, approximately 60 bloom 2 mM sodium azide. BLOCK- 0.02M sodium phosphate with 150 mm sodium chloride, ING: pH 7.4 4.0% w/w bovine serum albumin, fraction V by heat shock. 0.1% w/w gelatin, type B from bovine skin, approximately 60 bloom 2 mM sodium azide. INCUBA- 0.02M sodium phosphate with 150 mm sodium chloride, TION: pH 7.4 0.8% w/w bovine serum albumin, fraction V by heat shock. 0.1% w/w gelatin, type B from bovine skin, approx. 60 bloom 1% W/W normal goat serum 2 mM sodium azide.
Procedure: - 1. A nitrocellulose membrane, marked with pencilled divisions for antigen concentration identification, was simmered in gently boiling water for 15 minutes.
- 2. 1 μl dilutions of mouse IgG were spotted onto membrane, from 10−9 to 10−18 g.
- 3. Membrane was blocked with blocking buffer for 30 minutes at 45° C.
- 4. Membrane washed 5 minutes with wash buffer.
- 5. Membrane was incubated with 5 mL of a {fraction (1/200)} dilution of the NANOGOLD™ reagent in incubation buffer for 2.5 hours at room temperature, with slow agitation.
- 6. Membrane was rinsed with buffer 3 (3×5 mins), then PBS (3×30 seconds).
- 7. Membrane postfixed with glutaraldehyde, 1% in PBS (10 minutes).
- 8. Rinsed with deionized water (2×5 minutes).
- 9. Rinse with 0.05M EDTA at pH 4.5 (2 minutes).
- 10. Develop with freshly mixed LI SILVER™ (Nanoprobes, Inc.), 2×30 minutes. Rinse thoroughly with deionized water between developments to remove all the silver enhancement reagent.
- 11. Rinse repeatedly with deionized water, then let air-dry.
- The last visible spot in a series of decreasing concentration contained 10 pg of mouse IgG for platinum-labeled goat Fab′- and IgG-anti-mouse IgG, and also for palladium-labeled goat anti-mouse Fab′. For the IgG conjugates, this was the same level of sensitivity as was obtained from a second blot performed with the analogous Nanogold conjugate.
- Thiol-Gold Cluster Preparation and Antibody Labelling Procedure
- The following solutions are used in the preparation of thiol-gold clusters:
- A. NaBH4 solution: 0.2% solution of NaBH4 in ethanol.
- B. TEAH: 0.6M triethylammonium bicarbonate in distilled water. Note: Unless otherwise specified, all reactions are performed at 25° C.
16. Synthesis of Thiol Gold Cluster from Aurothioglucose (I): - 5 mg of aurothioglucose (C6H11O5SAu) is dissolved in 0.5 ml of distilled H2O in a test tube, forming a light yellow solution. Two 10 μL aliquots of NaBH4 solution are added to the aurothioglucose solution over 15 minutes. Upon NaBH4 addition the solution turns dark brown in color. The cluster is purified by size exclusion chromatography using Amicon GH-25 material (MW cutoff=3000 Daltons), with TEAH as the elution buffer. The cluster is recovered from the void volume of the column. Cluster formation is verified by UV/VIS spectroscopy and electron microscopy.
- 17. Synthesis of Thiol Gold Cluster from KAuBr4 and Glutathione
- (II): 5 mg of KAuBr4 (8.418×10−3 mMol) is dissolved in 0.3 ml of distilled water. 5.17 mg of glutathione (1.684×10−2 mMol), dissolved in 0.5 ml of distilled water is added to the KAuBr4 solution in two 0.25 ml aliquots at 5 minute intervals. After the first addition the dark reddish brown KAuBr4 solution turns to a clear, colorless to pale yellow solution. The reaction mixture is left for 5 minutes after the second addition of glutathione solution. The pH of the reaction mixture is adjusted to 8 using 6N NaOH solution. Two 10 μL aliquots of NaBH4 solution are added to the reaction mixture over 15 minutes. The pH is adjusted to neutral with 1N HCl solution, and a third 10 μL aliquot of NaBH4 solution is added. Two 10 μL aliquot of NaBH4 solution are added to the reaction mixture over 15 minutes. The pH is adjusted to neutral with 1N HCl solution, and a third 10 μL aliquot of NaBH4 solution is added. Upon NaBH4 addition the solution turns dark brown in color. The cluster is purified by size exclusion chromatography using Amicon GH-25 material (MW cutoff=3000 daltons), with TEAH as the elution buffer. The cluster is recovered from the void volume of the column. Cluster formation is verified by UV/VIS spectroscopy and electron microscopy.
- 18. Synthesis of a Mixed Thiol Gold cluster from KAuBr4 and a Mixture of Glutathione and 1-thio-.beta.-D-Glucose (III):
- 5 mg of KAuBr4 (8.418×10−3 mMol) is dissolved in 0.3 ml of distilled water. A mixed thiol solution of 3.62 mg of glutathione (1.18×10−2 mMol) and 1.10 mg of 1-thio-.beta.-D-Glucose (5.05×10−3 mMol), dissolved in 0.5 ml of distilled water is added to the KAuBr4 solution in two 0.25 ml aliquots at 5 minute intervals. After the first addition the dark reddish brown KAuBr4 solution turns to a clear, colorless to pale yellow solution. The reaction mixture is left for 5 minutes after the second addition of the mixed thiol solution. The pH of the reaction mixture is adjusted to 8 using 6N NaOH solution. Two 10 μL aliquots of NaBH4 solution are added to the reaction mixture over 15 minutes. The pH is adjusted to neutral with 1N HCl solution, and a third 10 μL aliquots of NaBH4 solution is added. Upon NaBH4 addition, the solution turns dark brown in color. The cluster is purified by size exclusion chromatography using Amicon GH-25 material (MW cutoff=3000 daltons), with TEAH as the elution buffer. The cluster is recovered from the void volume of the column. Cluster formation is verified by UV/VIS spectroscopy and electron microscopy.
- 19. Synthesis of Antibodies (Whole Molecule) Labelled with III:
- 2 mg of IgG is combined in a siliconized microcentrifuge tube with 10 mg of mercaptoethanolamine in 1.4 ml of 0.1M sodium phosphate, pH 6.0 which contains 5 mM EDTA. The reaction is allowed to proceed 1 hour at room temperature, then the reduced antibody is separated from excess MEA on a GH-25 column (Amicon), eluting with 0.1M borate buffer, pH 9.2, with 5 mM EDTA. The reduced antibody is collected in the void volume of the column. Fractions are combined and reduced in volume to 0.1 ml with centricon-30 (Amicon). The reduced antibody fraction is then incubated at 37° C. for 1 hour with a 20-fold excess of compound III, which is added in 0.1M borate buffer, pH 9.2, with 5 mM EDTA. The total volume of this reaction mixture is made up to 1.4 ml by adding 0.1M borate buffer, pH 9.2, with 5 mM EDTA. After incubation period, the reaction mixture is reduced in volume to 0.1 ml with centricon-30 (Amicon) and injected on a Superdex-75 molecular weight fractionation column (Pharmacia) to separate out the gold cluster-IgG conjugate from excess III. Antibody labelling is verified by UV/VIS spectroscopy and electron microscopy.
- 20. Synthesis of Fab′ Antibody Fragments Labelled with III:
- 2 mg of F(ab′)2 is combined in a siliconized microcentrifuge tube with 7 mg of mercaptoethanolamine in 1.4 ml of 0.1M sodium phosphate, pH 6.0 which contains 5 mM EDTA. The reaction is allowed to proceed 1 hour at room temperature, then the reduced antibody fragment is separated from excess MEA on a GH-25 column (Amicon), eluting with 0.1M borate buffer, pH 0.2, with 5 mM EDTA. The Fab′ fragment is collected in the void volume of the column. Fractions are combined and reduced in volume to 0.1 ml with centricon-30 (Amicon). The Fab′ fraction is then incubated at 37° C. for 1 hour with a 20-fold excess of III, which is added in 0.1M borate buffer, pH 9.2, with 5 mM EDTA. The total volume of this reaction mixture is made up to 1.4 ml by adding 0.1M borate buffer, pH 9.2, with 5 mM EDTA. After the incubation period, the reaction mixture is reduced in volume to 0.1 ml with centricon-30 (Amicon) and injected on a Superdex-75 molecular weight fractionation column (Pharmacia) to separate out the gold cluster-Fab′ conjugate from excess III. Antibody labelling is verified by UV/VIS spectroscopy and electron microscopy.
- Preparation of Thiol-Metal Clusters (Silver, Silver-Gold, Platinum, Thallium)
- 21. Preparation of Silver-Organic Thiol Clusters
- 5×10−6 moles of silver acetate in 0.5 ml of water was mixed with 1×10−5 moles of thioglucose and heated to 70° C. for 5 minutes. Then 5×10−6 moles of sodium borohydride was added. Later, 5×1 01 moles of additional sodium borohydride was added. A dark brown solution resulted, and contained organo-silver clusters ˜1-3 nm in diameter. These were purified by gel filtration size exclusion chromatography using an Amicon GH25 column (cutoff 3,000 MW) in an aqueous buffer of 0.6M triethylammonium bicarbonate and 5% methanol. The product was rotary evaporated under vacuum and resuspended in water. The size was assayed by electron microscopy.
- 22. Preparation of Mixed Silver-Gold Organic Thiol Clusters.
- 2.5×10−6 moles of silver acetate and 2.5×10−6 moles of chloroauric acid in 0.5 ml of water were mixed with 1×10−5 moles of thioglucose. Then, 5×10−6 moles of sodium borohydride was added. A dark brown solution resulted, and contained organo-silver/gold clusters ˜1-3 nm in diameter. These were purified by gel filtration size exclusion chromatography using an Amicon GH25 column (cutoff 3,000 MW) in an aqueous buffer of 0.6M triethylammonium bicarbonate and 5% methanol. The product was rotary evaporated under vacuum and resuspended in water. The size was assayed by electron microscopy.
- 23. Preparation of Platinum-Organic Thiol Clusters
- 5×10−6 moles of platinum chloride in 0.5 ml of water was mixed with 5×10−6 moles of thioglucose and heated to 60° C. for 5 minutes. Then 2.5×10−6 moles of sodium borohydride was added. Later, 2.5×106 moles of additional sodium borohydride was added. A dark brown solution resulted, and contained organo-platinum clusters ˜1-3 nm in diameter. These were purified by gel filtration size exclusion chromatography using an Amicon GH25 column (cutoff 3,000 MW) in an aqueous buffer of 0.6M triethylammonium bicarbonate and 5% methanol. The product was rotary evaporated under vacuum and resuspended in water. The size was assayed by electron microscopy.
- 24. Preparation of Thallium-Organic Thiol Clusters
- 5×10−6 moles of thallium chloride in 0.5 ml of water was mixed with 1×10−5 moles of thioglucose. After 10 minutes, 5×10−6 moles of sodium borohydride was added. Later, 2.5×10−6 moles of additional sodium borohydride was added. A dark brown solution resulted, and contained organo-thallium clusters ˜1-3 nm in diameter. These were purified by gel filtration size exclusion chromatography using an Amicon GH25 column (cutoff 3,000 MW) in an aqueous buffer of 0.6M triethylammonium bicarbonate and 5% methanol. The product was rotary evaporated under vacuum and resuspended in water. The size was assayed by electron microscopy.
- Thiol-Gold Clusters for Protein Staining in Polyacrylamide Gel Electrophoresis (PAGE): Preparation and Application
- The following solutions are used in the preparation of thiol-gold clusters:
- A. NaBH4 solution: 0.2% solution of NaBH4 in ethanol.
- B. TEAH: 0.6M triethylammonium bicarbonate in distilled water.
Note: Unless otherwise specified, all reactions are performed at 25° C.
25. Synthesis of Thiol-Gold Cluster from KAuBr4 and o-mercaptobenzoic Acid (1): - 5 mg of KAuBr4 (8.41×10−3 mMol) is dissolved in 0.3 ml of distilled water. 2.60 mg of o-mercaptobenzoic acid (1.68×1 0-2 mMol), dissolved in 0.5 ml of TEAH is added to the KAuBr4 solution in two 0.25 ml aliquots at 5 minute intervals. After the first addition, the dark reddish brown KAuBr4 solution turns to clear, colorless to pale yellow solution. The reaction mixture is left for 5 minutes after the second addition of glutathione solution. Two 10 μL aliquots of NaBH4 solution are added to the reaction mixture over 15 minutes. Upon NaBH4 addition the solution turns dark brown in color. The cluster is purified by size exclusion chromatography using Amicon GH25 material (MW cutoff=3000 daltons), with TEAH as the elution buffer. The cluster is recovered from the void volume of the column. The cluster containing fractions are combined in a 50 ml round bottom flask and the solution is evaporated to dryness with a rotoevaporator (Buchi). The cluster is redissolved in methanol and re-evaporated with the rotoevaporator. This methanol evaporation is done 5 times. The cluster is then dissolved in 0.1 sodium phosphate buffer, pH 8.0, with 1.0 mM EDTA for use in subsequent protein staining experiments. Cluster formation is verified by UV/VIS spectroscopy and electron microscopy. As a thiol scavenger, an excess amount of N-ethylmaleimide is added to the cluster solution.
- 26. Synthesis of a Mixed Thiol Gold Cluster from KAuBr4 and Mixture of o-mercaptobenzoic Acid and Nonylmercaptan(II):
- 5 mg of KAuBr4 (8.41×10−3 mMol) is dissolved in 0.3 ml of 90% ethanol in distilled H2O. A mixed thiol solution of 2.34 mg of o-mercaptobenzoic acid (1.52×10−2 mMol) and 0.27 mg of nonylmercaptan (1.68×10−3 mMol), dissolved in 0.5 ml of 95% ethanol in 6N NaOH, is added to the KAuBr4 solution in two 0.25 ml aliquots at 5 minute intervals. After the first addition, the dark reddish brown KAuBr4 solution turns to a pale yellow precipitate. Upon the addition of the second thiol mixture addition, the precipitate is solubilized to give a clear, colorless to pale yellow solution. The reaction mixture is left for 5 minutes after the second addition of the mixed thiol solution. Two 10 μL aliquots of NaBH4 solution are added to the reaction mixture over 15 minutes. The pH is adjusted to neutral with 1N HCl solution, and a third 10 μL aliquots of NaBH4 solution is added. Upon NaBH4 addition, the solution turns dark brown in color. The cluster is purified by size exclusion chromatography using Amicon GH-25 material (MW cutoff=3000 Daltons), with TEAH as the elution buffer. The cluster is recovered from the void volume of the column. The cluster containing fractions are combined in a 50 ml round bottom flask and the solution is evaporated to dryness with a rotoevaporator (Buchi). The cluster is redissolved in methanol and re-evaporated with the rotoevaporator. This methanol evaporation is done 5 times. The cluster is then dissolved in 0.1 sodium phosphate buffer, pH 8.0, with 1.0 mM EDTA for use in subsequent protein staining experiments. Cluster formation is verified by UV/VIS spectroscopy and electron microscopy. As a thiol scavenger, an excess amount of N-ethylmaleimide is added to the cluster solution.
- 27. Application of I and II to SDS-PAGE in Non-Reducing Conditions:
- Protein sample (Pharmacia LMW calibration kit proteins) to be analyzed is incubated with excess I or II in 10 mM Tris/HCl, 1 mM EDTA, pH 8.0. To the sample is added Sodium Dodecyl Sulphate (SDS) to 2.5%. The sample is heated for 5 minutes at 100° C. Bromophenol Blue is added to 0.01%. Using an eight “well” sample applicator, eight 1 μL aliquots of the sample mixture are applied to a Phastgel gradient gel (8-25) and run on the Pharmacia Phastgel system using the following protocol:
Sample Applicator down at step 1.1 1 Vh Sample Applicator up at step 1.1 10 Vh SEP 1.1 250 V 10.0 mA 3.0 W 15° C. 65 Vh SEP 1.2 50 V 0.1 mA 0.5 W 15° C. 0 Vh - After electrophoresis, the gel is developed for 5-15 minutes (or until background development) with LI SILVER silver enhancement kit (Nanoprobes, Inc.). After silver development, gels are rinsed thoroughly with deionized water, and preserved by incubation in 20% glycerol in deionized water at 45° C. for 10 minutes.
- 28. Application of I and II to SDS-PAGE in Reducing Conditions:
- Protein sample (Pharmacia LMW calibration kit proteins) to be analyzed is incubated with a 2.5% mercaptosuccinic acid solution in 10 mM Tris/HCl, 1 mM EDTA, pH 8.0. To the sample is added Sodium Dodecyl Sulphate (SDS) to 2.5%. The sample is heated for 5 minutes at 100° C. Bromophenol Blue is added to 0.01% and N-ethylmaleimide (prepared as a 20% solution in DMSO) is added to 5%. The sample is incubated at room temperature for 10 minutes. Excess amounts of I and II are added to the sample mixture. Using an eight “well” sample applicator, eight 1 μL aliquots of the sample mixture are applied to a Phastgel gradient gel (8-25) and run on the Pharmacia Phastgel system using the following protocol:
Sample Applicator down at step 1.1 1 Vh Sample Applicator up at step 1.1 10 Vh SEP 1.1 250 V 10.0 mA 3.0 W 15° C. 65 Vh SEP 1.2 50 V 0.1 mA 0.5 W 15° C. 0 Vh - After electrophoresis, the gel is developed for 5-15 minutes (or until background development) with LI SILVER silver enhancement kit (Nanoprobes, Inc.). After silver development, gels are rinsed thoroughly with deionized water, and preserved by incubation in 20% glycerol in deionized water at 45° C. for 10 minutes.
- Detection of Oligonucleotides
- General:
- Oligonucleotides modified to contain biotin can be detected through the use of either gold cluster labeled anti-biotin antibodies, antibody fragments, gold cluster-labeled streptavidin, or gold cluster-labeled avidin. Incorporation of the biotin into an oligonucleotide strand can occur via a commercially available biotin-NHS reagent and a primary amine that was introduced onto the oligonucleotide via a modified nucleotide or nucleotide substitute (phosphoramidite) by a DNA synthesizer. The biotin labeled oligonucleotide can then be reacted with gold cluster labeled reagent designed to react with the biotin moiety and observed via silver development.
- 29. An oligonucleotide having a primary amine attached to the 5′ end was reacted in sightly alkaine sodium phosphate buffer with a large molar excess of biotin-LC-N-hydroxysuceinimide ester (biotin-LC-NHS II; Pierce) dissolved in DMSO. After 1 hour at room temperature the reaction mixture was purified on a GH25 (nominal exclusion limit 3000 D) column and fractions measured for nucleic acid content by monitoring at 260 nm. By comparing the ratio of the 260 and 240 nm peaks to gauge biotin incorporation. Recovered nucleic acid yield 49%.
- The biotin labeled oligonucleotides were reacted with streptavidin gold cluster conjugates in phosphate buffered saline (PBS), pH 7.4 for four hours at room temperature and separated by size exclusion chromatography (Superdex 75, nominal exclusion limit 70 kD) using the same buffer as eluant. On this column, the major peak coincided with the retention time of the cluster conjugate and showed enhanced absorption at 260 nm indicating reaction had occurred.
- 30. Detection of Biotinylated DNA: Dot Blots
- Blot tests were conducted to test the incorporation of gold in the isolated product. In a typical run, biotin labeled oligonucleotides was serially diluted in water by factors of ten starting with a 2.5×10−7 M solution and ending at 2.5×10−166 M. 1 μL spots were applied to a nitrocellulose membrane by Drummond capillary pipettes. The membrane was allowed to dry and then subjected to a 302 nm light placed 18 cm from the membrane for ten minutes. The membrane was blocked with 4% bovine serum albumin (BSA) for 30 minutes at 37° C. The membrane was then incubated with the streptavidin gold cluster conjugate diluted to about 2 μg/ml in 0.8% BSA for 1.5 hours. After rinsing with buffer and then water, the membrane was treated with silver developer. The membrane was again rinsed with water and examined for spot generation after drying. The silver developed gold particle is seen as a dark spot. The spots appearing unambiguously above background provide a limit of detection on the order of 10 to 100 attomole (1 attomol=10−188 mol) detected with more concentrated applications appearing darker than dilute ones.
- 31. Preparation and Detection of Biotinylated M13mp18
- Another model system was the preparation of labeled complementary fragments to the single stranded phage M13mp18. Using the random primer method, biotin was introduced as modified dUTP and incorporated with Klenow. After purification using GeneClean, the biotinylated solution was applied to a nitrocellulose membrane, immobilized in a vacuum oven and detected by streptavidin gold cluster conjugate. In this procedure 10−15 mol M13mp18 was detected. The detection limit was independent of the concentration of the gold conjugate.
- Preparation of Gold Cluster Labeled DNA Hybridization Probes
- 32. Random Primer Extension Method
- Gold cluster labelled nucleotide triphosphate was prepared by reaction of NHS-gold cluster with an amino modified nucleotide triphosphate. Example: Amino-7-dUTP, available from Clontech, is a dUTP analog with a primary amine covalently attached to the pyrimidine ring through a seven atom spacer arm. 50 nmol Amino-7-dUTP was reacted with 5 nmol mono-N-hydroxy-sulfosuccinimide-1.4 nm gold cluster in 20 mM HEPES-NaOH buffer pH 7.5 at 4° C. overnight. The reaction mixture was separated on a GH25 column to remove unreacted nucleotide from the conjugate. The product was further purified by ion exchange chromatography over TSK DEAE with elution at 0.3M triethylammonium hydrogencarbonate.
- The modified nucleotide was incorporated into an oligonucleotide by enzymatic extension of random primers.
- While the invention has been described by reference to specific embodiments, this was for purposes of illustration only. Numerous alternative embodiments will be apparent to those skilled in the art and are considered to be within the scope of the invention.
Claims (44)
1. A cluster complex or colloid comprising:
a plurality of core particles, each of the core particles being composed of a solid metal; and
a plurality of probe molecules covalently attached to the core particles, the probe molecules functionalizing the cluster complex or colloid to target at least one other substance or to endow the particles with specified properties.
2. The cluster complex or colloid of claim 1 wherein the core particles are less than 2 microns in size.
3. The cluster complex or colloid of claim 1 wherein the metal of the core particles is gold, platinum, silver, palladium, or combinations thereof.
4. The cluster complex or colloid of claim 1 wherein the probe molecules are covalently bonded to the core particles by a specific reaction of the probe molecules with a functional group incorporated into an outer surface of the core particle by means of chemical synthesis or modification, the functional group being selected from the group comprising maleimide, N-hydroxysuccinimide, Sulfo-N-hydroxysuccinimide, aliphatic amine, 1,2-dihydroxy, aldehyde, nitrilotriaceitic acid (NTA) or its chelate with nickel, copper, iron, cobalt, or other transition metal.
5. The cluster complex or colloid of claim 4 further comprising nucleic acids, DNA, or RNA covalently bonded to the core particles by the functional group.
6. The cluster complex or colloid of claim 1 wherein the covalently attached probe molecules are selected from the group comprising antibodies, antibody fragments, avidin or streptavidin, peptides, drugs, antigens, hormones, DNA, and RNA.
7. The clusters or colloids of claim 1 further comprising a plurality of fluorescently labeled molecules covalently attached to the core particles, wherein the chemistry for covalently attaching the probe molecules and the fluorescently labeled molecules to the core particles controls the fluorophore of the fluorescently labeled molecules.
8. The cluster complex or colloid of claim 1 further comprising a plurality of lipid molecules attached to the core particles.
9. The cluster complex or colloid of claim 1 further comprising nucleic acids, DNA, or RNA.
10. The cluster complex or colloid of claim 1 further comprising a plurality of antibody fragments.
11. The cluster complex or colloid of claim 1 further comprising a polymer coating the core particles, the polymer being chosen from a group containing linear or branched polymer with functional groups, polyamino acids, polyethylene derivatives, and mixtures thereof.
12. The cluster complex or colloid of claim 1 wherein the core particles are composed of gold and the probe molecules are fluorescent dyes.
13. The cluster complex or colloid of claim 12 wherein the fluorescent dye is Hoescht-33258.
14. The cluster complex or colloid of claim 1 wherein the probe molecule is streptavidin.
15. A method for detecting a substance comprising mixing a sample suspected of containing the substance with a cluster complex or a colloid comprising a plurality of metal core particles and a plurality of probe molecules covalently attached to the core particles, the probe molecules functionalizing the cluster complex or colloid to target the substance.
16. The method of 15 further comprising the step of detecting the substance with a piezoelectric crystal mass measuring device.
17. The method of claim 15 further comprising the step of detecting the substance by using changes in reflected light from a surface.
18. The method of claim 15 further comprising the step of detecting the substance using light microscopy.
19. The method of claim 15 further comprising the step of visualizing the localization or distribution of the substance within cells, tissue sections, organelles or organs using light microscopy.
20. The method of claim 15 further comprising the step of detecting the substance using fluorescent microscopy.
21. The method of claim 15 further comprising the step of visualizing the localization or distribution of the substance within cells, tissue sections, organelles or organs using fluorescent microscopy.
22. The method of claim 15 further comprising the step of detecting the substance using confocal microscopy.
23. The method of claim 15 further comprising the step of visualizing the localization or distribution of the substance within cells, tissue sections, organelles or organs using confocal microscopy.
24. The method of claim 15 further comprising the step of detecting the substance using electron microscopy.
25. The method of claim 15 further comprising the step of visualizing the localization or distribution of the substance within cells, tissue sections, organelles or organs using electron microscopy.
26. The method of claim 15 wherein the cluster complex or colloid further comprises a plurality of fluorescently labeled molecules covalently attached to the core particles, the chemistry for covalently attaching the probe molecules and the fluorescently labeled molecules to the core particles controls the fluorophore of the fluorescently labeled molecules, and wherein the method further comprises the step of detecting the substance using both light, fluorescence or confocal microscopy and electron microscopy.
27. The method of claim 15 wherein the cluster complex or colloid further comprises a plurality of fluorescently labeled molecules covalently attached to the core particles, the chemistry for covalently attaching the probe molecules and the fluorescently labeled molecules to the core particles controls the fluorophore of the fluorescently labeled molecules, and wherein the method further comprises the step of visualizing the localization or distribution of the substance within cells, tissue sections, organelles or organs using both light, fluorescence or confocal microscopy and electron microscopy.
28. The method of claim 15 further comprising the step of detecting the substance on blots, immunochromatographic lateral flow assay devices, or test strips.
29. A metal cluster comprising:
a plurality of metal core particles; and
a plurality of organic thiols covalently bound to the core particles through a thiol moiety, the organic thiols being selected from the group comprising alkyl thiols, aryl thiols, proteins containing thiol, peptides or nucleic acids with thiol, glutathione, cysteine, thioglucose, thiol benzoic acid, antibodies, lipids, and carbohydrates.
30. A metal colloid comprising:
a plurality of metal colloid particles; and
a plurality of organic thiols covalently bound to the core particles through a thiol moiety, the organic thiols being selected from the group comprising alkyl thiols, aryl thiols, proteins containing thiol, peptides or nucleic acids with thiol, glutathione, cysteine, thioglucose, thiol benzoic acid, antibodies, lipids, and carbohydrates.
31. A metal colloid comprising:
a plurality of metal colloid particles; and
a polymer coating the metal colloid particles.
32. The metal colloid of claim 31 further comprising a plurality of covalently bonded molecules selected from the group including proteins, peptides, antibodies, lipids, carbohydrates, nucleic acids, drugs, and hormones.
33. A process for coating metal colloid particles comprising synthesizing the metal colloid in the presence of a polymer.
34. The process of claim 33 further comprising the step of stabilizing the polymer coating on the metal colloid particle by warming the coated particle to 60°-100° C., microwave heating, chemical crosslinking, continued polymerization, or photocrosslinking.
35. A process for coating metal colloid particles comprising mixing preformed metal colloid particles with a polymer.
36. The process of claim 35 further comprising the step of stabilizing the polymer coating on the metal colloid particle by warming the coated particle to 60°-100° C., microwave heating, chemical crosslinking, continued polymerization, or photocrosslinking.
37. A process for covalently incorporating organometallic particles into nucleic acids comprising using an organometallic particle containing a nucleic acid base or nucleic acid analog as a substrate in automated nucleic acid synthesis.
38. A process for covalently incorporating organometallic particles into nucleic acids comprising using an organometallic particle attached to a nucleic acid base or analog in enzymatic nucleic acid synthesis.
39. A process for covalently incorporating organometallic particles into nucleic acids comprising reacting an organometallic particle with functional groups incorporated into nucleic acids.
40. A process for covalently incorporating organometallic particles into nucleic acids comprising reacting organometallic particles containing photoactive groups with nucleic acids.
41. A process of exchanging thiol-containing molecules on metal particles by incubating preformed metal particles containing bound thiol molecules with a new thiol-containing molecule, whereby the new thiol-containing molecule attaches to the metal particle.
42. The process of claim 41 where the new thiol-containing molecule is chosen from whole IgG and Fab′ antibody fragments.
43. A method for imparting specific chemical, spectroscopic, or electrochemical properties or functions to a larger macromolecular array or construct by covalently bonding a plurality of probe molecules onto a plurality of metal core particles, the probe molecules being covalently bonded to the core particles by a specific reaction of the probe molecules with a functional group incorporated into an outer surface of the core particle by means of chemical synthesis or modification, the functional group being selected from the group comprising maleimide, N-hydroxysuccinimide, Sulfo-N-hydroxysuccinimide, aliphatic amine, 1,2-dihydroxy, aldehyde, nitrilotriaceitic acid (NTA) or its chelate with nickel, copper, iron, cobalt, or other transition metal.
44. A method for detecting changes in the conformation or binding of probe molecules attached to specific targets, the probe molecules being covalently attached to metal core particles, the probe molecules functionalizing the cluster complex or colloid to the target, the method comprising measuring changes in the fluorescence properties of conjugated molecules labeled with fluorescent tags.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/988,781 US20050130207A1 (en) | 1994-07-29 | 2004-11-15 | Small organometallic probes |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/282,929 US5521289A (en) | 1994-07-29 | 1994-07-29 | Small organometallic probes |
US08/652,007 US5728590A (en) | 1994-07-29 | 1996-05-23 | Small organometallic probes |
US09/039,601 US6121425A (en) | 1994-07-29 | 1998-03-16 | Metal-lipid molecules |
US09/619,343 US6369206B1 (en) | 1994-07-29 | 2000-07-19 | Metal organothiol particles |
US10/093,770 US6818199B1 (en) | 1994-07-29 | 2002-03-08 | Media and methods for enhanced medical imaging |
US10/988,781 US20050130207A1 (en) | 1994-07-29 | 2004-11-15 | Small organometallic probes |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/093,770 Continuation US6818199B1 (en) | 1994-07-29 | 2002-03-08 | Media and methods for enhanced medical imaging |
Publications (1)
Publication Number | Publication Date |
---|---|
US20050130207A1 true US20050130207A1 (en) | 2005-06-16 |
Family
ID=33425460
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/093,770 Expired - Fee Related US6818199B1 (en) | 1994-07-29 | 2002-03-08 | Media and methods for enhanced medical imaging |
US10/988,781 Abandoned US20050130207A1 (en) | 1994-07-29 | 2004-11-15 | Small organometallic probes |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/093,770 Expired - Fee Related US6818199B1 (en) | 1994-07-29 | 2002-03-08 | Media and methods for enhanced medical imaging |
Country Status (1)
Country | Link |
---|---|
US (2) | US6818199B1 (en) |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080279946A1 (en) * | 2007-05-09 | 2008-11-13 | Nanoprobes, Inc. | Methods and compositions for increasing infrared absorptivity of a target |
US20090098574A1 (en) * | 2006-04-25 | 2009-04-16 | Centre National De La Recherche Scientifique (Cnrs) | Functionalization of gold nanoparticles with oriented proteins, application to the high-density labelling of cell membranes |
US20100278923A1 (en) * | 2008-02-27 | 2010-11-04 | National Chiao Tung University | Functional nanoparticle-based antibiotics and preparation method thereof |
US20110110858A1 (en) * | 2009-11-11 | 2011-05-12 | Omer Aras | Gold nanoparticle imaging agents and uses thereof |
US20110123452A1 (en) * | 2009-11-25 | 2011-05-26 | Nanoprobes, Inc. | Metal oligomers and polymers and their use in biology and medicine |
WO2012003617A1 (en) * | 2010-07-05 | 2012-01-12 | 深圳大学 | Immuno-chromatographic detection device and detection method thereof |
US20120052513A1 (en) * | 2010-08-24 | 2012-03-01 | Pradeep Thalappil | Gold sub-nanoclusters and uses thereof |
EP2952897A1 (en) * | 2008-04-09 | 2015-12-09 | Becton, Dickinson and Company | Sensitive immunoassays using coated nanoparticles |
TWI511971B (en) * | 2014-12-22 | 2015-12-11 | Ind Tech Res Inst | Probe and method for detecting metal ions and chemical/biochemical molecules |
CN106662580A (en) * | 2014-08-06 | 2017-05-10 | 健康与环境慕尼黑德国研究中心赫姆霍茨中心(有限责任公司) | Novel cluster for the detection of an analyte |
US9739773B1 (en) | 2010-08-13 | 2017-08-22 | David Gordon Bermudes | Compositions and methods for determining successful immunization by one or more vaccines |
CN108289650A (en) * | 2015-11-10 | 2018-07-17 | 皇家飞利浦有限公司 | Computed tomography imaging method |
Families Citing this family (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6417138B1 (en) * | 1994-07-26 | 2002-07-09 | Sony Corporation | Method for transcribing an image and a support for transcription and ink ribbon employed therefor |
US20050013775A1 (en) * | 2000-06-01 | 2005-01-20 | Kotov Nicholas A. | Bioconjugates of nanoparticles as radiopharmaceuticals |
EP1450863A4 (en) * | 2001-11-07 | 2009-01-07 | Imcor Pharmaceutical Company | Methods for vascular imaging using nanoparticulate contrast agents |
US20060177852A1 (en) * | 2001-12-12 | 2006-08-10 | Do-Coop Technologies Ltd. | Solid-fluid composition |
WO2003082213A2 (en) * | 2002-03-28 | 2003-10-09 | Imcor Pharmaceutical Company | Compositions and methods for delivering pharmaceutically active agents using nanoparticulates |
US20040133100A1 (en) * | 2002-08-23 | 2004-07-08 | Morteza Naghavi | Novel risk assessment method based upon coronary calcification distribution pattern imaged by computed tomography |
US7927275B2 (en) * | 2002-08-26 | 2011-04-19 | The Cleveland Clinic Foundation | System and method of aquiring blood-vessel data |
JP2006524087A (en) * | 2003-04-22 | 2006-10-26 | コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ | Equipment for angiographic radiography |
US7894880B2 (en) * | 2003-10-23 | 2011-02-22 | The Board Of Trustees Of The Leland Stanford Junior University | Measurement of renal extraction fraction using contrast enhanced computed tomography |
US20070003482A1 (en) * | 2004-01-15 | 2007-01-04 | Koninklijke Philips Electronic, N.V. | Ultrasound contrast agents for molecular imaging |
US20070031337A1 (en) * | 2004-06-22 | 2007-02-08 | Reinhard Schulte | Nanoparticle enhanced proton computed tomography and proton therapy |
US9005663B2 (en) * | 2004-08-31 | 2015-04-14 | The Curators Of The University Of Missouri | Methods for producing silver nanoparticles |
US20060079746A1 (en) * | 2004-10-11 | 2006-04-13 | Perret Florence M | Apparatus and method for analysis of tissue classes along tubular structures |
US9358310B2 (en) | 2007-09-17 | 2016-06-07 | The Curators Of The University Of Missouri | EGCG stabilized gold nanoparticles and method for making same |
US8333994B2 (en) | 2007-09-17 | 2012-12-18 | The Curators Of The University Of Missouri | Stabilized, biocompatible gold nanoparticles and enviro-friendly method for making same |
EP1824521B1 (en) * | 2004-11-19 | 2015-01-07 | Koninklijke Philips N.V. | Ultrasound contrast agents for molecular imaging |
DE102005028882A1 (en) * | 2005-06-22 | 2007-01-04 | Siemens Ag | A solution and method for assisting imaging on a patient |
US7524354B2 (en) * | 2005-07-07 | 2009-04-28 | Research Foundation Of State University Of New York | Controlled synthesis of highly monodispersed gold nanoparticles |
GB0514513D0 (en) * | 2005-07-15 | 2005-08-24 | Ge Healthcare Ltd | Particulate agents |
US8241393B2 (en) * | 2005-09-02 | 2012-08-14 | The Curators Of The University Of Missouri | Methods and articles for gold nanoparticle production |
US20070121784A1 (en) * | 2005-09-20 | 2007-05-31 | Sectra Mamea Ab | X-ray imaging arrangement |
US20070122620A1 (en) * | 2005-11-02 | 2007-05-31 | General Electric Company | Nanoparticle-based imaging agents for x-ray / computed tomography and methods for making same |
US20070098641A1 (en) * | 2005-11-02 | 2007-05-03 | General Electric Company | Nanoparticle-based imaging agents for X-ray/computed tomography |
US9149545B2 (en) * | 2005-11-02 | 2015-10-06 | General Electric Company | Nanoparticle-based imaging agents for X-ray/computed tomography and methods for making same |
US20090004296A1 (en) * | 2006-01-04 | 2009-01-01 | Do-Coop Technologies Ltd. | Antiseptic Compositions and Methods of Using Same |
AU2007203961A1 (en) * | 2006-01-04 | 2007-07-12 | Do-Coop Technologies Ltd. | Solid-fluid composition |
US7829140B1 (en) | 2006-03-29 | 2010-11-09 | The Research Foundation Of The State University Of New York | Method of forming iron oxide core metal shell nanoparticles |
US7906147B2 (en) * | 2006-10-12 | 2011-03-15 | Nanoprobes, Inc. | Functional associative coatings for nanoparticles |
WO2008081455A2 (en) * | 2007-01-04 | 2008-07-10 | Do-Coop Technologies Ltd. | Detection of analytes |
KR20090106578A (en) * | 2007-01-04 | 2009-10-09 | 두-쿱 테크놀로지스 리미티드 | Composition and method for enhancing cell growth and cell fusion |
US8343627B2 (en) * | 2007-02-20 | 2013-01-01 | Research Foundation Of State University Of New York | Core-shell nanoparticles with multiple cores and a method for fabricating them |
WO2009005752A1 (en) * | 2007-06-28 | 2009-01-08 | The Curators Of The University Of Missouri | Stabilized gold nanoparticle and contrast agent |
US8784846B2 (en) * | 2007-07-30 | 2014-07-22 | Loma Linda University Medical Center | Systems and methods for particle radiation enhanced delivery of therapy |
US8586096B2 (en) | 2007-10-01 | 2013-11-19 | The Curators Of The University Of Missouri | Soy or lentil stabilized gold nanoparticles and method for making same |
US20120107229A1 (en) * | 2009-04-15 | 2012-05-03 | Xuefei Huang | Novel nano-probes for molecular imaging and targeted therapy of diseases |
US9107895B2 (en) * | 2009-07-24 | 2015-08-18 | The University Of Chicago | Methods and compositions for imaging cancer cells |
US20110044900A1 (en) * | 2009-08-22 | 2011-02-24 | Yeu-Kuang Hwu | Method for treating and/or diagnosing tumor by gold particles coated with a polymer |
EP2513630B1 (en) * | 2009-12-17 | 2016-05-25 | Chris Geddes | A detection system using mixed-metal substrates for metal-enhanced fluorescence |
JP2013526616A (en) | 2010-05-26 | 2013-06-24 | ザ ジェネラル ホスピタル コーポレイション | Magnetic nanoparticles |
WO2012007456A1 (en) * | 2010-07-12 | 2012-01-19 | Ge Healthcare As | X-ray imaging at low contrast agent concentrations and/or low dose radiation |
CN103079642A (en) * | 2010-07-16 | 2013-05-01 | 丹麦科技大学 | Nanoparticle-guided radiotherapy |
TW201212942A (en) * | 2010-09-28 | 2012-04-01 | Univ Nat Cheng Kung | CT/MRI dual modality molecular imaging contrast agent and method for manufacturing the same |
US20120083690A1 (en) * | 2010-10-04 | 2012-04-05 | Semenov Serguei Y | System and method for electromagnetic imaging and therapeutics using specialized nanoparticles |
CN103582500A (en) | 2011-06-06 | 2014-02-12 | 俄勒冈州,由高等教育州委员会代表俄勒冈州立大学 | Bismuth particle X-ray contrast agents |
WO2014159759A1 (en) | 2013-03-13 | 2014-10-02 | Biosphere Medical, Inc. | Compositions and associated methods for radioisotope-binding microparticles |
WO2014145509A1 (en) * | 2013-03-15 | 2014-09-18 | The Regents Of The University Of California | Enteric ct contrast material based on low-z atoms |
US20200255976A1 (en) | 2017-10-23 | 2020-08-13 | Montrose Biosystems Llc | Single- and mixed-metal nanoparticles, nanoparticle conjugates, devices for making nanoparticles, and related methods of use |
Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4101646A (en) * | 1970-05-13 | 1978-07-18 | Rikagaku Kenkyusho | Ferrite vascular contrast media |
US4313734A (en) * | 1978-07-13 | 1982-02-02 | Akzona Incorporated | Metal sol particle immunoassay |
US5019370A (en) * | 1989-07-10 | 1991-05-28 | University Of Kentucky Research Foundation | Biodegradable, low biological toxicity radiographic contrast medium and method of x-ray imaging |
US5120643A (en) * | 1987-07-13 | 1992-06-09 | Abbott Laboratories | Process for immunochromatography with colloidal particles |
US5344940A (en) * | 1990-11-30 | 1994-09-06 | Warner-Lambert Company | Intermediates for individual stereoisomers of 7-[3-(aminoalkyl)-1-pyrrolidinyl]-quinolones and naphthyridones |
US5360895A (en) * | 1987-04-22 | 1994-11-01 | Associated Universities, Inc. | Derivatized gold clusters and antibody-gold cluster conjugates |
US5443813A (en) * | 1991-06-06 | 1995-08-22 | Associated Universities, Inc. | Loading and conjugating cavity biostructures |
US5521289A (en) * | 1994-07-29 | 1996-05-28 | Nanoprobes, Inc. | Small organometallic probes |
US5707986A (en) * | 1994-03-14 | 1998-01-13 | Miller; Joan W. | Angiographic method using green porphyrins in primate eyes |
US6369206B1 (en) * | 1994-07-29 | 2002-04-09 | Robert D. Leone | Metal organothiol particles |
US6521773B1 (en) * | 2000-07-21 | 2003-02-18 | James F. Hainfeld | Extended organic cobalt and nickel magnetic complexes |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5750150A (en) | 1992-09-18 | 1998-05-12 | Traditional Chinese Medicine Research Laboratory, Inc. | Compositions for treating affected tissues, method for the preparation and usage thereof |
US5798349A (en) | 1994-03-14 | 1998-08-25 | The General Hospital Corporation | Use of green porphyrins to treat neovasculature in the eye |
JPH10330288A (en) | 1997-06-03 | 1998-12-15 | Mitsubishi Chem Corp | Metal fine particle complex and contrast media by using the same |
IT1297396B1 (en) | 1997-12-30 | 1999-09-01 | Francesco Buzzigoli | METHOD AND DEVICE FOR THE RECONSTRUCTION OF THREE-DIMENSIONAL IMAGES OF BLOOD VESSELS, IN PARTICULAR OF CORONARY ARTERIES, OR OF OTHER |
US6203778B1 (en) | 1998-12-08 | 2001-03-20 | The Regents Of The University Of California | Particulate radiopaque contrast agent for diagnostic imaging and microvascular characterization |
US6265875B1 (en) | 1999-05-17 | 2001-07-24 | General Electric Company | Method and apparatus for efficient MRI tissue differentiation |
-
2002
- 2002-03-08 US US10/093,770 patent/US6818199B1/en not_active Expired - Fee Related
-
2004
- 2004-11-15 US US10/988,781 patent/US20050130207A1/en not_active Abandoned
Patent Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4101646A (en) * | 1970-05-13 | 1978-07-18 | Rikagaku Kenkyusho | Ferrite vascular contrast media |
US4313734A (en) * | 1978-07-13 | 1982-02-02 | Akzona Incorporated | Metal sol particle immunoassay |
US5360895A (en) * | 1987-04-22 | 1994-11-01 | Associated Universities, Inc. | Derivatized gold clusters and antibody-gold cluster conjugates |
US5120643A (en) * | 1987-07-13 | 1992-06-09 | Abbott Laboratories | Process for immunochromatography with colloidal particles |
US5019370A (en) * | 1989-07-10 | 1991-05-28 | University Of Kentucky Research Foundation | Biodegradable, low biological toxicity radiographic contrast medium and method of x-ray imaging |
US5344940A (en) * | 1990-11-30 | 1994-09-06 | Warner-Lambert Company | Intermediates for individual stereoisomers of 7-[3-(aminoalkyl)-1-pyrrolidinyl]-quinolones and naphthyridones |
US5443813A (en) * | 1991-06-06 | 1995-08-22 | Associated Universities, Inc. | Loading and conjugating cavity biostructures |
US5707986A (en) * | 1994-03-14 | 1998-01-13 | Miller; Joan W. | Angiographic method using green porphyrins in primate eyes |
US5521289A (en) * | 1994-07-29 | 1996-05-28 | Nanoprobes, Inc. | Small organometallic probes |
US6369206B1 (en) * | 1994-07-29 | 2002-04-09 | Robert D. Leone | Metal organothiol particles |
US6521773B1 (en) * | 2000-07-21 | 2003-02-18 | James F. Hainfeld | Extended organic cobalt and nickel magnetic complexes |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090098574A1 (en) * | 2006-04-25 | 2009-04-16 | Centre National De La Recherche Scientifique (Cnrs) | Functionalization of gold nanoparticles with oriented proteins, application to the high-density labelling of cell membranes |
US20080279946A1 (en) * | 2007-05-09 | 2008-11-13 | Nanoprobes, Inc. | Methods and compositions for increasing infrared absorptivity of a target |
US8323694B2 (en) | 2007-05-09 | 2012-12-04 | Nanoprobes, Inc. | Gold nanoparticles for selective IR heating |
US20100278923A1 (en) * | 2008-02-27 | 2010-11-04 | National Chiao Tung University | Functional nanoparticle-based antibiotics and preparation method thereof |
EP2952897A1 (en) * | 2008-04-09 | 2015-12-09 | Becton, Dickinson and Company | Sensitive immunoassays using coated nanoparticles |
US20110110858A1 (en) * | 2009-11-11 | 2011-05-12 | Omer Aras | Gold nanoparticle imaging agents and uses thereof |
US20110123452A1 (en) * | 2009-11-25 | 2011-05-26 | Nanoprobes, Inc. | Metal oligomers and polymers and their use in biology and medicine |
WO2012003617A1 (en) * | 2010-07-05 | 2012-01-12 | 深圳大学 | Immuno-chromatographic detection device and detection method thereof |
US9739773B1 (en) | 2010-08-13 | 2017-08-22 | David Gordon Bermudes | Compositions and methods for determining successful immunization by one or more vaccines |
US20120052513A1 (en) * | 2010-08-24 | 2012-03-01 | Pradeep Thalappil | Gold sub-nanoclusters and uses thereof |
CN106662580A (en) * | 2014-08-06 | 2017-05-10 | 健康与环境慕尼黑德国研究中心赫姆霍茨中心(有限责任公司) | Novel cluster for the detection of an analyte |
CN105717077A (en) * | 2014-12-22 | 2016-06-29 | 财团法人工业技术研究院 | Probe, method for detecting metal ion, and method for detecting chemical/biochemical molecule |
US9664664B2 (en) | 2014-12-22 | 2017-05-30 | Industrial Technology Research Institute | Probe and method for detecting metal ions and chemical/biochemical molecules |
TWI511971B (en) * | 2014-12-22 | 2015-12-11 | Ind Tech Res Inst | Probe and method for detecting metal ions and chemical/biochemical molecules |
CN108289650A (en) * | 2015-11-10 | 2018-07-17 | 皇家飞利浦有限公司 | Computed tomography imaging method |
Also Published As
Publication number | Publication date |
---|---|
US6818199B1 (en) | 2004-11-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20050130207A1 (en) | Small organometallic probes | |
US5521289A (en) | Small organometallic probes | |
US6369206B1 (en) | Metal organothiol particles | |
US5728590A (en) | Small organometallic probes | |
US4898951A (en) | Compounds used as intermediates in the preparations of non-radioactive biological probes | |
US5985566A (en) | Platinum-containing compounds, methods for their preparation and applications thereof | |
JP2777330B2 (en) | Immunologically active complexes and methods for their production | |
JP2866419B2 (en) | Rare earth cryptate, its production method, its synthetic intermediate and its use as a fluorescent tracer | |
KR101153748B1 (en) | NOVEL Au/Ag CORE SHELL COMPOSITE USEFUL FOR BIOSENNOVEL Au/Ag CORE SHELL COMPOSITE USEFUL FOR BIOSENSOR SOR | |
US7364872B1 (en) | Test methods using enzymatic deposition and alteration of metals | |
US7041459B2 (en) | Analyzing phosphorylated proteins | |
JP2003531213A (en) | Metal chelating composite | |
EP1019420B1 (en) | Methods for the production of platinum-based linkers between labels and bio-organic molecules, for labelling bio-organic molecules, for detecting biological substances of interest | |
JP3583415B2 (en) | Core-shell metal particles coated with dextran or aminodextran bearing SH groups, and uses thereof | |
WO2002065132A2 (en) | Detectable compositions, methods of forming the same and detection techniques | |
JP4098839B2 (en) | Indocyanine compounds | |
JP5592057B2 (en) | Labeled transition metal complex | |
JPH0717672B2 (en) | Cobalamin-acid hydrazide, its production method and cobalamin conjugate | |
JP3488670B2 (en) | Homobifunctional reagent that binds enzymes etc. to antibodies etc. | |
EP0155854B1 (en) | Non-radioactive biological probes | |
Hainfeld et al. | Eleven tungsten atom cluster labels: high-resolution, site-specific probes for electron microscopy. | |
Cais | [35] Metalloimmunoassay: Principles and practice | |
Hersh et al. | Preparation, characterization, and use of an antiserum specific for 2 ‘, 5 ‘-oligoadenylates. | |
EP0973785B1 (en) | Trans-platinum compound, and diagnostic kit | |
Powell et al. | Giant platinum clusters: 2-nm covalent metal cluster labels |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |